Pyrazole derivatives, their preparation and pharmaceutical applications
Pyrazole derivatives are developed to selectively inhibit PRMT5 in MTAP-deficient tumor cells, addressing the challenge of targeting PRMT5 in both malignant and healthy cells, thereby minimizing side effects and enhancing treatment efficacy.
Patent Information
- Application Number
- JP2024531734
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-01-14
- Filing Date
- 2022-11-09
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-11-09
AI Technical Summary
Current strategies to inhibit PRMT5 enzyme, crucial for various diseases, face challenges in selectively targeting MTAP-deficient tumor cells without affecting normal tissues, due to PRMT5's role in both malignant and healthy cells, leading to significant side effects.
Development of pyrazole derivatives that act as selective inhibitors of PRMT5, designed to target the enzyme only when it is in an MTA-bound state, prevalent in MTAP-deficient tumor cells, thereby minimizing impact on normal cells.
The pyrazole derivatives effectively inhibit PRMT5 in tumor cells while reducing side effects on normal tissues, providing a therapeutic window for treating PRMT5-mediated diseases.
Smart Images

Figure 2024543188000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention belongs to the field of drug synthesis, in particular to pyrazole derivatives, their preparation methods and applications in pharmacy. [Background technology]
[0002] Epigenetic gene regulation is an important biological regulatory mechanism for protein synthesis and cell differentiation and plays a key role in many human diseases. Epigenetic regulation involves the regulation of heritable genetic material without altering the nucleic acid sequence. Typically, epigenetic regulation controls the conversion of transcriptionally active and inactive states in chromatin conformation by selective and reversible modifications (e.g., methylation) to DNA and proteins (e.g., histones). These covalent modifications can be controlled by enzymes such as methyltransferases (e.g., PRMT5), many of which are associated with specific genetic alterations in many human disease-causing genes. PRMT5 plays an important role in many diseases, e.g., tumors, metabolic disorders, and hematological disorders.
[0003] Homozygous deletion of tumor suppressor genes is a tumor driver and often leads to the deletion of passenger genes near the suppressor genes. These passenger gene deletions result in specific vulnerabilities of tumor cells and can be targeted with targeted therapy. Homozygous deletion of the chromosome 9p21 site containing the well-known tumor suppressor gene CDKN2A occurs in 15% of tumors and often includes deletion of the passenger gene MTAP. MTAP is a key enzyme in the methionine and adenine recycling pathway. Deletion of MTAP leads to accumulation of its substrate MTA. MTA is structurally similar to S-adenosylmethionine (SAM), the methyl substrate donor for the type II methyltransferase PRMT5. Increased MTA levels due to deletion of MTAP can selectively compete with SAM for PRMT5 binding, rendering the methyltransferase ineffective and more susceptible to PRMT5 inhibition. This metabolic sensitivity effect has come into the spotlight because many different genome-wide shRNA screens applied to a wide range of tumor cell lines have shown a correlation between MTAP loss and PRMT5 dependency in the cell lines. However, PRMT5 is a very important gene for cells, and all studies on conditional or siRNA knockout of PRMT5 suggest that inhibiting PRMT5 in normal tissues will result in significant side effects (e.g., decreased blood cells, infertility, decreased skeletal muscle, cardiac hypertrophy, etc.). Therefore, new strategies are needed to apply and explore metabolic sensitivity by selectively targeting PRMT5 in MTAP-deficient tumors while avoiding the effects on PRMT5 in normal tissues (MTAP wild type).
[0004] Small molecule inhibitors targeting PRMT5 in cooperation with MTA can selectively target only PRMT5, which is enriched only in MTAP-deficient tumor cells in association with MTA, and therefore PRMT5 is not targeted when MTA levels are very low in MTAP-intact normal cells, providing a better therapeutic window. Summary of the Invention [Problem to be solved by the invention]
[0005] The object of the present invention is to provide pyrazole derivatives, their preparation methods and pharmaceutical applications. The compounds of the present invention have strong inhibitory effects on PRMT5, and can be widely used in the preparation of drugs for treating and / or preventing diseases mediated by PRMT5, and are expected to lead to the development of new generation PRMT5 inhibitors. [Means for solving the problem]
[0006] A first aspect of the present invention provides a compound of formula (I), a stereoisomer thereof or a pharma- ceutically acceptable salt thereof,
[0007] [ka]
[0008] where L is a bond, O, S, C(O), C(O)O, C(O)NH, CH=CH, C≡C, S(O), S(O)2, NR 12 , S(O)2NH or CR 13 R 14 and X1, X2 and X3 each independently represent N or CR. 15 and R1 is hydrogen, deuterium, hydroxyl group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 aryl and 5-10 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl groups, C 3-12 Cycloalkoxy group, 3-12 membered heterocyclic group, 3-12 membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22R 23 and optionally further substituted by one or more substituents selected from R2 is hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, halo-substituted C 1-10 Alkyl group, deuterium substituted C 1-10 Alkyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 Selected from R3, R4, R5, R6 and R7 each independently represent hydrogen, deuterium, a halogen, a cyano group, a nitro group, an azide group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22)R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 or two adjacent substituents among R3, R4, R5, R6, and R7 form a 4-8 membered carbocyclic ring, a 4-8 membered heterocyclic ring, a 6-8 membered aromatic ring, or a 5-8 membered heteroaromatic ring together with the moiety to which they are directly linked, said groups being independently selected from deuterium, halogen, a cyano group, a nitro group, an azide group, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21, -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R8 is hydrogen, deuterium, hydroxyl group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 aryl and 5-10 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl groups, C 3-12 Cycloalkoxy group, 3-12 membered heterocyclic group, 3-12 membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R9 is hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 3-12Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 Selected from R 10 and R 11are independently hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R22 )-C(O)R 21 or R 10 and R 11 is a carbon atom directly connected to C(O), C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups, C 6-10 aryl or 5-8 membered heteroaryl groups, which groups are independently selected from deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R 12 is hydrogen, deuterium, hydroxyl group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 aryl and 5-10 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl groups, C 3-12 Cycloalkoxy group, 3-12 membered heterocyclic group, 3-12 membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R 13 and R 14 are independently hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17, -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 or R 13 and R 14 is a carbon atom directly connected to C(O), C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups, C 6-10 aryl or 5-8 membered heteroaryl groups, which groups are independently selected from deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium-substituted C1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21and optionally further substituted by one or more substituents selected from Each R 15 are independently hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 wherein the groups are independently selected from deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted with one or more substituents selected from R 15 is hydrogen, then at least one of R3, R4, R5, R6 and R7 is a 3-8 membered nitrogen-containing heterocyclic group, said nitrogen atom being linked to a benzene ring; Each R 16 are independently hydrogen, deuterium, and C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)R 21 Or -C 0-8 Alkyl-C(O)NR 22 R 23 The group is selected from deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from Each R 17 and R 18 are independently hydrogen, deuterium, hydroxyl group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups, C 6-10 aryl or 5-10 membered heteroaryl group, or R 17 and R18 forms a 3-10 membered heterocyclic group together with the sulfur atom to which it is directly linked, said group being selected from the group consisting of deuterium, halogen, cyano group, nitro group, azide group, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21, -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from Each R 19 are independently hydrogen, deuterium, hydroxyl group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups and -NR 22 R 23 wherein the groups are independently selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl groups, C 3-12 Cycloalkoxy group, 3-12 membered heterocyclic group, 3-12 membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from Each R 20 are independently hydrogen, deuterium, and C 1-10 Alkyl group, C 2-10 Alkenyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 aryl and 5-10 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, cyano, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl groups, C 3-12 Cycloalkoxy group, 3-12 membered heterocyclic group, 3-12 membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22 R23 and optionally further substituted by one or more substituents selected from Each R 21 are independently hydrogen, deuterium, hydroxyl group, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, C 3-12 Cycloalkoxy group, 3-12 membered heterocyclic group, 3-12 membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22 R 23 wherein the groups are independently selected from deuterium, halogen, a hydroxy group, ═O, a cyano group, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl groups, C 3-12 Cycloalkoxy group, 3-12 membered heterocyclic group, 3-12 membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from Each R 22 and R 23 are independently hydrogen, deuterium, hydroxyl group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl group, 5- to 10-membered heteroaryl group, sulfinyl group, sulfonyl group, methylsulfonyl group, isopropylsulfonyl group, cyclopropylsulfonyl group, p-toluenesulfonyl group, aminosulfonyl group, dimethylaminosulfonyl group, and C 1-10 alkanoyl groups, said groups being independently selected from deuterium, halogen, hydroxyl groups, ═O, C 1-10 Alkyl group, C2-10 Alkenyl group, C 2-10 Alkynyl group, halo-substituted C 1-10 Alkyl group, deuterium substituted C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl groups, C 3-12 Cycloalkoxy group, 3-12 membered heterocyclic group, 3-12 membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group, amino group, C 1-10 Alkyl mono-substituted amino group, C 1-10 Alkyl bis-substituted amino group and C 1-10 or R 22 and R 23 forms a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group together with the nitrogen atom to which it is directly bonded, and the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is not deuterium, halogen, a hydroxyl group, ═O, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, halo-substituted C 1-10 Alkyl group, deuterium substituted C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl groups, C 3-12 Cycloalkoxy group, 3-12 membered heterocyclic group, 3-12 membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group, amino group, C 1-10 Alkyl monosubstituted amino group, C 1-10 Alkyl disubstituted amino groups and C 1-10 Optionally further substituted by one or more substituents selected from alkanoyl groups; Each r is independently 0, 1, or 2.
[0009] In a more preferred embodiment, in the compound of formula (I), its stereoisomer, or its pharma- ceutically acceptable salt, L is a bond, O, S, C(O), S(O), S(O)2, NR 12 or CR 13 R 14 and X1, X2 and X3 each independently represent N or CR. 15 and R1 is hydrogen, deuterium, hydroxyl group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 aryl and 5-8 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R2 is hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, halo-substituted C 1-4 Alkyl group, deuterium substituted C 1-4 Alkyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 16 )R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R18 , -C 0-4 Alkyl-OS(O)2R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 )R 19 , -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-SC(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 )R 21 , -C 0-4 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 Selected from R3, R4, R5, R6 and R7 each independently represent hydrogen, deuterium, a halogen, a cyano group, a nitro group, an azide group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 16 )R 17 , -C 0-4 Alkyl-N=S(O)R17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-OS(O)2R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 )R 19 , -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-SC(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 )R 21 , -C 0-4 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 or two adjacent substituents among R3, R4, R5, R6, and R7 form a 5-8 membered carbocyclic ring, a 5-8 membered heterocyclic ring, a 6 membered aromatic ring, or a 5-6 membered heteroaromatic ring with the moiety to which they are directly linked, said groups being independently selected from deuterium, halogen, a cyano group, a nitro group, an azide group, C 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 16 )R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-OS(O)2R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 )R 19 , -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-SC(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 )R 21 , -C 0-4 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R8 is hydrogen, deuterium, hydroxyl group, C 1-4Alkyl group, C 2-4 Alkenyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 aryl and 5-8 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R9 is hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, halo-substituted C 1-4 Alkyl group, deuterium substituted C 1-4 Alkyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 16 )R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-OS(O)2R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 )R 19 , -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20, -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-SC(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 )R 21 , -C 0-4 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 Selected from R 10 and R 11 are independently hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 16 )R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-OS(O)2R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 )R 19, -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-SC(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 )R 21 , -C 0-4 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 or R 10 and R 11 is a carbon atom directly connected to C(O), C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 aryl or 5-6 membered heteroaryl groups, which groups are independently selected from deuterium, halogen, cyano, nitro, azide, C 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 16 )R 17 , -C 0-4 Alkyl-N=S(O)R 17 R18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-OS(O)2R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 )R 19 , -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-SC(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 )R 21 , -C 0-4 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R 12 is hydrogen, deuterium, hydroxyl group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 aryl and 5-8 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl group, C 1-4 Alkoxy group, C3-6 Cycloalkyl groups, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R 13 and R 14 are independently hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 16 )R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-OS(O)2R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 )R 19 , -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-SC(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 )R 21 , -C 0-4 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 or R 13 and R 14 is a carbon atom directly connected to C(O), C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 aryl or 5-6 membered heteroaryl groups, which groups are independently selected from deuterium, halogen, cyano, nitro, azide, C 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 16 )R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-OS(O)2R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 )R 19 , -C 0-4 Alkyl-OR 20 , -C0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-SC(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 )R 21 , -C 0-4 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from Each R 15 are independently hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 16 )R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-OS(O)2R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4Alkyl-P(O)(OR 20 )R 19 , -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-SC(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 )R 21 , -C 0-4 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 wherein the groups are independently selected from deuterium, halogen, cyano, nitro, azide, C 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 16 )R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4Alkyl-OS(O)2R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 )R 19 , -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-SC(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 )R 21 , -C 0-4 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted with one or more substituents selected from R 15 is hydrogen, then at least one of R3, R4, R5, R6 and R7 is a 3-8 membered nitrogen-containing heterocyclic group, said nitrogen atom being linked to a benzene ring; Here, R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 and r are as described for compounds of formula (I).
[0010] In a more preferred embodiment, in the compound of formula (I), its stereoisomer, or its pharma- ceutically acceptable salt, each R 16 are independently hydrogen, deuterium, and C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, -S(O) r R 19 , -C(O)OR 20 , -C(O)R 21 or -C(O)NR 22 R 23 The group is selected from deuterium, halogen, cyano, nitro, azide, C 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -SF5, -S(O)(=NR 16 )R 17 , -N=S(O)R 17 R 18 , -N=SR 17 R 18 , -OS(O)2R 19 , -S(O) r R 19 , -P(O)(OR 20 )R 19 , -OR 20 , -C(O)OR 20 , -C(O)SR 20 , -SC(O)R 21 , -C(O)R 21 , -OC(O)R 21 , -NR 22 R 23 , -C(=NR 22 )R 21 , -N(R 22 )-C(=NR 23 )R 21 , -C(O)NR 22R 23 and Il-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from Each R 17 and R 18 are independently hydrogen, deuterium, hydroxyl group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 aryl or 5-8 membered heteroaryl group, or R 17 and R 18 forms a 4-6 membered heterocyclic group together with the sulfur atom to which it is directly linked, said group being selected from the group consisting of deuterium, halogen, cyano group, nitro group, azide group, C 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -SF5, -S(O)(=NR 16 )R 17 , -N=S(O)R 17 R 18 , -N=SR 17 R 18 , -OS(O)2R 19 , -S(O) r R 19 , -P(O)(OR 20 )R 19 , -OR 20 , -C(O)OR 20 , -C(O)SR 20 , -SC(O)R 21 , -C(O)R 21 , -OC(O)R 21 , -NR 22 R 23 , -C(=NR 22 )R 21 , -N(R 22 )-C(=NR 23 )R21 , -C(O)NR 22 R 23 and -N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from Each R 19 are independently hydrogen, deuterium, hydroxyl group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups and -NR 22 R 23 wherein the groups are independently selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from Each R 20 are independently hydrogen, deuterium, and C 1-4 Alkyl group, C 2-4 Alkenyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 aryl and 5-8 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, cyano, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23and optionally further substituted by one or more substituents selected from Each R 21 are independently hydrogen, deuterium, hydroxyl group, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 wherein the groups are independently selected from deuterium, halogen, a hydroxy group, ═O, a cyano group, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from Each R 22 and R 23 are independently hydrogen, deuterium, hydroxyl group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, sulfinyl groups, sulfonyl groups, methylsulfonyl groups, isopropylsulfonyl groups, cyclopropylsulfonyl groups, p-toluenesulfonyl groups, aminosulfonyl groups, dimethylaminosulfonyl groups and C 1-4 alkanoyl groups, said groups being independently selected from deuterium, halogen, hydroxyl groups, ═O, C 1-4Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group, amino group, C 1-4 Alkyl-substituted amino group, C 1-4 Alkyl-disubstituted amino groups and C 1-4 or R 22 and R 23 forms a 4-6 membered heterocyclic group or a 5-6 membered heteroaryl group together with the nitrogen atom to which it is directly bonded, and the 4-6 membered heterocyclic group or the 5-6 membered heteroaryl group is not deuterium, halogen, a hydroxyl group, ═O, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group, amino group, C 1-4 Alkyl-substituted amino group, C 1-4 Alkyl-disubstituted amino groups and C 1-4 Optionally further substituted by one or more substituents selected from alkanoyl groups; Each r is independently 0, 1, or 2.
[0011] In a more preferred embodiment, in the compound of formula (I), its stereoisomer, or its pharma- ceutically acceptable salt, the compound of formula (I) has a structure of a compound of formula (II) below:
[0012] [ka]
[0013] where X1 is N or CH and X2 is N or CR 15 and R1 is hydrogen, deuterium, C 1-4 Alkyl group, C 3-6 cycloalkyl groups and 3-6 membered heterocyclic groups, said groups being independently selected from deuterium, halogen, hydroxyl groups, ═O, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R3, R4, R5, R6 and R7 each independently represent hydrogen, deuterium, a halogen, a cyano group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 16 )R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4Alkyl-OS(O)2R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 )R 19 , -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-SC(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 )R 21 , -C 0-4 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 or two adjacent substituents among R3, R4, R5, R6, and R7 form a 5-8 membered carbocyclic ring, a 5-8 membered heterocyclic ring, a 6 membered aromatic ring, or a 5-6 membered heteroaromatic ring with the moiety to which they are directly linked, said groups being independently selected from deuterium, halogen, cyano group, C 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4Alkyl-S(O)(=NR 16 )R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-OS(O)2R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 )R 19 , -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-SC(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 )R 21 , -C 0-4 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R 10 and R 11 are independently hydrogen, deuterium, halogen, cyano group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 or R 10 and R 11 is a carbon atom directly connected to C(O), C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 aryl or 5-6 membered heteroaryl groups, which groups are independently selected from deuterium, halogen, cyano, C 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3-6 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(O)NR 22 R23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R 15 is hydrogen, deuterium, cyano group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 16 )R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-OS(O)2R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 )R 19 , -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-SC(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 )R 21 , -C 0-4 Alkyl-N(R 22 )-C(=NR 23 )R 21, -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 wherein the groups are independently selected from deuterium, halogen, cyano, C 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OR 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-OC(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted with one or more substituents selected from R 15 is hydrogen, then at least one of R3, R4, R5, R6 and R7 is a 3-8 membered nitrogen-containing heterocyclic group, and said nitrogen atom is connected to a benzene ring; Here, R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 and r are as described for compounds of formula (I).
[0014] In a more preferred embodiment, in the compound of formula (I), its stereoisomer, or its pharma- ceutically acceptable salt, the compound of formula (I) has a structure of a compound of formula (III):
[0015] [ka]
[0016] Here, ring A has the following structure:
[0017] [ka] or
[0018] [ka] and
[0019] R1 is selected from hydrogen, deuterium, a methyl group, an ethyl group, an isopropyl group, and a cyclopropyl group; Each R3 and R7 is independently hydrogen, deuterium, fluorine, chlorine, a cyano group, C 1-4 Alkyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, hydroxy groups, methoxy groups, ethoxy groups, isopropoxy groups, C 3-8 selected from a cycloalkoxy group, a 3- to 8-membered heterocyclic oxy group, a methylthio group, an ethylthio group, a carboxyl group, a methoxycarbonyl group, an ethoxycarbonyl group, an isopropoxycarbonyl group, an acetyl group, an acetoxy group, an amino group, a dimethylamino group, an acetylamino group, and a carbamoyl group; R 15 is selected from a cyano group, an ethynyl group, a cyclopropyl group, or hydrogen;
[0020] R 15 is selected from a cyano group, an ethynyl group, or a cyclopropyl group, and ring A is
[0021] [ka] When R4 and R 6a are each independently halogen, C 1-4 Alkoxy group, C 3-8 A cycloalkoxy group, a 3- to 8-membered heterocyclic group, or a 3- to 8-membered heterocyclic oxy group, 1-4 Alkoxy group, C 3-8 The cycloalkoxy group, the 3- to 8-membered heterocyclic group, and the 3- to 8-membered heterocyclic oxy group each independently represent a deuterium atom, a halogen atom, a cyano group, 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -SF5, -OR 20 , -C(O)OR 20 , -C(O)R 21 , -OC(O)R 21 , -NR 22 R 23 , -C(O)NR 22 R 23 and -N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from
[0022] R 15 is selected from a cyano group, an ethynyl group, or a cyclopropyl group, and ring A is
[0023] [ka] If R 6b is hydrogen, deuterium, fluorine, chlorine, cyano group, C 1-4 Alkyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, hydroxy groups, methoxy groups, ethoxy groups, isopropoxy groups, C 3-8 selected from a cycloalkoxy group, a 3- to 8-membered heterocyclic oxy group, a carboxyl group, an amino group, and a dimethylamino group;
[0024] R 15 is selected from hydrogen and ring A is
[0025] [ka] When R4 and R 6a are each independently halogen, C 1-4 Alkoxy group, C 3-8 A cycloalkoxy group, a 3- to 8-membered heterocyclic group, or a 3- to 8-membered heterocyclic oxy group, 1-4 Alkoxy group, C 3-8 The cycloalkoxy group, the 3- to 8-membered heterocyclic group, and the 3- to 8-membered heterocyclic oxy group each independently represent a deuterium atom, a halogen atom, a cyano group, 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -SF5, -OR 20 , -C(O)OR 20 , -C(O)R 21 , -OC(O)R 21 , -NR 22 R 23 , -C(O)NR 22 R 23 and -N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R and R 6a At least one of the nitrogen atoms is a 3-8 membered nitrogen-containing heterocyclic group, the nitrogen atom of which is bonded to a benzene ring, and the 3-8 membered nitrogen-containing heterocyclic group is free of deuterium, halogen, cyano group, C 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -SF5, -OR 20 , -C(O)OR 20 , -C(O)R 21 , -OC(O)R 21 , -NR 22 R 23 , -C(O)NR 22 R 23 and -N(R 22 )-C(O)R 21 provided that the compound is optionally further substituted with one or more substituents selected from
[0026] Here, R 20 , R 21 , R 22 and R 23 is as described for compounds of formula (I). In a more preferred embodiment, in the compound of formula (I), its stereoisomer, or its pharma- ceutically acceptable salt, the compound of formula (I) has a structure of a compound of the following formula (IVa):
[0027] [ka]
[0028] Here, R 15 is selected from a cyano group, an ethynyl group, or a cyclopropyl group; Ring A has the following structure:
[0029] [ka] or
[0030] [ka] and
[0031] R4 and R 6a are each independently halogen, C 1-4 Alkoxy group, C 3-8A cycloalkoxy group, a 3- to 8-membered heterocyclic group, or a 3- to 8-membered heterocyclic oxy group, 1-4 Alkoxy group, C 3-8 The cycloalkoxy group, the 3- to 8-membered heterocyclic group, and the 3- to 8-membered heterocyclic oxy group each independently represent a deuterium atom, a halogen atom, a cyano group, 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -SF5, -OR 20 and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R 6b is hydrogen, deuterium, fluorine, chlorine, cyano group, C 1-4 Alkyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, hydroxy groups, methoxy groups, ethoxy groups, isopropoxy groups, C 3-8 is selected from the group consisting of a cycloalkoxy group, a 3- to 8-membered heterocyclic oxy group, a carboxyl group, an amino group, and a dimethylamino group, where R 20 , R 22 and R 23 is as described for compounds of formula (I).
[0032] In a further preferred embodiment, in the compound of formula (I), its stereoisomer, or its pharma- ceutically acceptable salt, R4 and R 6aare each independently selected from fluorine, chlorine, a cyclopropoxy group, a cyclobutoxy group, and a 3- to 8-membered nitrogen-containing heterocyclic group, and the cyclopropoxy group, cyclobutoxy group, and the 3- to 8-membered nitrogen-containing heterocyclic group are each independently selected from deuterium, fluorine, chlorine, a cyano group, a methyl group, an ethyl group, a n-propyl group, an isopropyl group, a trifluoromethyl group, a difluoromethyl group, a trideuteromethyl group, a diduteromethyl group, a vinyl group, an ethynyl group, a cyclopropyl group, a cyclobutyl group, an oxetanyl group, an azetidinyl group, a phenyl group, -SF5, =O, a hydroxy group, a methoxy group, an ethoxy group, a n-propyloxy group, an isopropyloxy group, an amino group, a mono-C 1-4 Alkylamino group and diC 1-4 optionally further substituted by one or more substituents selected from alkylamino groups; R 6b is selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, hydroxy, methoxy, ethoxy, isopropoxy, cyclopropoxy, cyclobutoxy, carboxyl, amino, and dimethylamino.
[0033] In a more preferred embodiment, in the compound of formula (I), its stereoisomer, or its pharma- ceutically acceptable salt, the compound of formula (I) has a structure of a compound of the following formula (IVb):
[0034] [ka]
[0035] Where R4 and R 6a are each independently halogen, C 1-4 Alkoxy group, C 3-8 A cycloalkoxy group, a 3- to 8-membered heterocyclic group, or a 3- to 8-membered heterocyclic oxy group, 1-4 Alkoxy group, C 3-8 The cycloalkoxy group, the 3- to 8-membered heterocyclic group, and the 3- to 8-membered heterocyclic oxy group each independently represent a deuterium atom, a halogen atom, a cyano group,1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -SF5, -OR 20 and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R and R 6a at least one of the nitrogen atoms is a 3-8 membered nitrogen-containing heterocyclic group, the nitrogen atom being linked to a benzene ring, and the 3-8 membered nitrogen-containing heterocyclic groups each independently contain deuterium, halogen, a cyano group, C 1-4 Alkyl, halo-substituted C 1-4 Alkyl group, deuterium substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl groups, 5-8 membered heteroaryl groups, =O, =S, -SF5, -OR 20 and -NR 22 R 23 provided that the compound is optionally further substituted with one or more substituents selected from Here, R 20 , R 22 and R 23 is as described for compounds of formula (I).
[0036] In a further preferred embodiment, in the compound of formula (I), its stereoisomer, or its pharma- ceutically acceptable salt, R4 and R 6aare each independently selected from fluorine, chlorine, a cyclopropoxy group, a cyclobutoxy group, and a 3- to 8-membered nitrogen-containing heterocyclic group, and the cyclopropoxy group, cyclobutoxy group, and the 3- to 8-membered nitrogen-containing heterocyclic group are each independently selected from deuterium, fluorine, chlorine, a cyano group, a methyl group, an ethyl group, a n-propyl group, an isopropyl group, a trifluoromethyl group, a difluoromethyl group, a trideuteromethyl group, a diduteromethyl group, a vinyl group, an ethynyl group, a cyclopropyl group, a cyclobutyl group, an oxetanyl group, an azetidinyl group, a phenyl group, -SF5, =O, a hydroxy group, a methoxy group, an ethoxy group, a n-propyloxy group, an isopropyloxy group, an amino group, a mono-C 1-4 Alkylamino group and diC 1-4 and optionally further substituted with one or more substituents selected from an alkylamino group, R4 and R 6a at least one of the nitrogen atoms is a 3-8 membered nitrogen-containing heterocyclic group, the nitrogen atom being linked to a benzene ring, and the 3-8 membered nitrogen-containing heterocyclic group each independently comprises one or more of deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, trideuteromethyl, diduteromethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, phenyl, -SF5, =O, hydroxy, methoxy, ethoxy, n-propyloxy, isopropyloxy, amino, mono-C 1-4 Alkylamino group and diC 1-4 provided that it is optionally further substituted with a substituent selected from alkylamino groups.
[0037] In a more preferred embodiment, in the compound of formula (I), its stereoisomer or its pharma- ceutically acceptable salt, the 3- to 8-membered nitrogen-containing heterocyclic group is selected from the following structures:
[0038] [ka]
[0039] In the most preferred form, the compound of formula (I), its stereoisomer or its pharma- ceutically acceptable salt includes, but is not limited to, the following compounds:
[0040] [ka] TIFF2024543188000016.tif231170TIFF2024543188000017.tif110168
[0041] A second aspect of the present invention provides a method for producing a compound of formula (I), its stereoisomer, or a pharma- ceutically acceptable salt thereof, the method comprising the steps of synthesizing a compound of formula (IA) or a salt thereof and a compound of formula (IB) or a salt thereof by a condensation reaction to obtain a compound of formula (I) or a salt thereof, the reaction pathway being as follows:
[0042] [ka]
[0043] The above-mentioned production method can be carried out using a general condensation reaction in the art according to the definition of L, for example,
[0044] If L is a bond, R a is a halogen, R b is -B(OH)2 or [ka] or R a is -B(OH)2 or [ka] Halogen, R b is a halogen,
[0045] If L is O, then R a is a hydroxyl or alkoxy group, R b is a halogen or R ais a halogen, R b is a hydroxy group or an alkoxy group, If L is S, then R a is a mercapto group or an alkylthio group, and R b is a halogen or R a is a halogen, R b is a mercapto group or an alkylthio group, When L is C(O), C(O)O, or C(O)NH, R a is a carboxyl group or an alkoxycarbonyl group, and R b is a halogen, a hydroxyl group, or an amino group, or R a is a halogen, a hydroxyl group, or an amino group, and R b is a carboxyl group or an alkoxycarbonyl group, Here, R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , X1, X2, X3 are as defined for compounds of formula (I).
[0046] A third aspect of the present invention provides a pharmaceutical composition comprising a compound of formula (I), a stereoisomer thereof or a pharma- ceutically acceptable salt thereof, and a pharmaceutical carrier. A fourth aspect of the present invention provides the use of the compound of formula (I), its stereoisomer or its pharma- ceutically acceptable salt in the manufacture of a medicament for treating MATP-associated cancer or tumor.
[0047] In a preferred embodiment, the tumor or cancer is selected from the group consisting of endometrial adenocarcinoma, granulosaccinomas, testicular Sertoli cell tumors, germ cell tumors, malignant teratomas, squamous cell carcinomas, carcinoma in situ, adenocarcinomas, fibrosarcomas, melanomas, clear cell carcinomas, squamous cell carcinomas, botryoid sarcomas, fallopian tube carcinomas, adenocarcinomas, nephroblastomas, lymphomas, leukemias, bladder cancers, squamous cell carcinomas, transitional cell carcinomas, adenocarcinomas, prostate cancers, seminoma, teratomas, fetal carcinomas, teratomas, choriocarcinomas, sarcomas, interstitial cell carcinomas, fibromas, fibroadenomas, adenomatous tumors, lipomas, and liver tumors. Cancer, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, gallbladder cancer, ampullary carcinoma, bile duct carcinoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, birthmark, dysplastic nevus, lipoma, hemangioma, acute and chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome, Hodgkin's disease, non-Hodgkin's lymphoma, osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, multiple myeloma Myeloma, Malignant giant cell tumor chordoma, Osteochondroma, Benign chondroma, Chondroblastoma, Chondromyxofibroma, Osteoid osteoma, Giant cell tumor, Angiosarcoma, Fibrosarcoma, Rhabdomyosarcoma, Liposarcoma, Myxoma, Rhabdomyocele, Fibroma, Lipoma and Teratoma, Bronchiolungal carcinoma, Alveolar carcinoma, Bronchial adenoma, Sarcoma, Lymphoma, Chondromatous hamartoma, Mesothelioma, Squamous cell carcinoma, Adenocarcinoma, Leiomyosarcoma, Lymphoma, Gastric cancer, Lymphoma, Leiomyosarcoma, Ductal adenocarcinoma, Insulinoma, Glucagonoma, Gastrinomas, Carcinomas The tumor is selected from the group consisting of tumors, venom tumors, adenocarcinomas, lymphomas, carcinoid tumors, Kaposi's sarcoma, leiomyomas, hemangiomas, lipomas, neurofibromas, fibromas, colon adenocarcinomas, tubular adenomas, villous adenomas, hamartomas, leiomyomas, craniomas, hemangiomas, granulomas, xanthomas, osteitis deformans, meningiomas, meningeal sarcomas, gliomatosis, astrocytoma, medulloblastomas, gliomas, ependymoma, germ cell tumors, glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors, spinal neurofibromas, meningiomas, gliomas, and sarcomas.
[0048] More preferably, the cancer or tumor is selected from breast cancer, pancreatic cancer, skin cancer, bladder cancer, liver cancer, or head and neck cancer. The present invention also relates to the compound of the above formula (I), its stereoisomer or a pharma- ceutically acceptable salt thereof, for use as a PRMT5 inhibitor drug.
[0049] The present invention also relates to the use of the compound of formula (I), its stereoisomer or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and / or prevention of a disease mediated by PRMT5.
[0050] The present invention also relates to a method for treating and / or preventing a disease mediated by PRMT5, comprising administering to a patient in need thereof a therapeutically effective amount of the compound of formula (I) as defined above, its stereoisomer or a pharma- ceutically acceptable salt thereof. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0051] The inventors of the present application have conducted extensive and in-depth research and have, for the first time, researched and developed a PRMT5 inhibitor having the structure of the following formula (I). The series of compounds of the present invention can be widely applied to the manufacture of drugs for treating and / or preventing diseases mediated by PRMT5, and are expected to be developed as a new generation of PRMT5 inhibitors. Based on this, the present invention has been completed.
[0052] DETAILED DESCRIPTION: Unless stated to the contrary or otherwise explained, the following terms used in the specification and claims have the following meanings. The term "alkyl group" refers to a linear or branched saturated aliphatic hydrocarbon group, preferably a linear alkyl group or a branched alkyl group containing 1 to 10 or 1 to 6 carbon atoms or 1 to 4 carbon atoms, and examples thereof include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a t-butyl group, an s-butyl group, an n-pentyl group, a 1,1-dimethylpropyl group, a 1,2-dimethylpropyl group, a 2,2-dimethylpropyl group, a 1-ethylpropyl group, a 2-methylbutyl group, a 3-methylbutyl group, an n-hexyl group, a 1-ethyl-2-methylpropyl group, a 1,1,2-trimethylpropyl group, a 1,1-dimethylbutyl group, a 1,2-dimethylbutyl group, a 2,2-dimethylbutyl group, a 1,3-dimethylbutyl group, a 2-ethylbutyl group, a 2-methylpentyl group, a 3-methylbutyl group, a 2-methylpentyl ... Examples of the alkyl groups include, but are not limited to, butyl pentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, or various branched isomers thereof. 1-10 "Alkyl group" refers to a straight chain alkyl group or a branched chain alkyl group containing 1 to 10 carbon atoms. 1-4 "Alkyl group" refers to a straight chain alkyl group or a branched chain alkyl group containing 1 to 4 carbon atoms. 0-8 "Alkyl group" refers to a straight chain alkyl group or a branched chain alkyl group containing 0 to 8 carbon atoms. 0-4 The term "alkyl group" refers to straight chain and branched chain alkyl groups containing 0 to 4 carbon atoms.
[0053] The alkyl group may be optionally substituted or unsubstituted, but if substituted, the substituents may be independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 It is preferable that the number of the groups is one or more (preferably 1, 2, 3 or 4) selected from the following:
[0054] The term "cycloalkyl group" or "carbocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent. The partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2 or 3) double bonds, but none of the rings has a completely conjugated π-electron system. The cycloalkyl group is divided into a monocyclic cycloalkyl group and a polycyclic cycloalkyl group, and is preferably a cycloalkyl group containing 3 to 12, 3 to 8 or 3 to 6 carbon atoms, and examples of the cycloalkyl groups include "C 3-12 "Cycloalkyl group" refers to a cycloalkyl group containing 3 to 12 carbon atoms. 4-8 "Cycloalkyl group" refers to a cycloalkyl group containing 4 to 8 carbon atoms. 3-8 "Cycloalkyl group" refers to a cycloalkyl group containing 3 to 8 carbon atoms. 3-6 "Cycloalkyl group" refers to a cycloalkyl group containing 3 to 6 carbon atoms, in which Monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like.
[0055] Polycyclic cycloalkyl groups include spiro, fused and bridged ring cycloalkyl groups. "Spirocycloalkyl groups" refer to polycyclic groups that share one carbon atom (called a spiro atom) between monocyclic rings, and these groups may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated pi-electron system. Depending on the number of spiro atoms shared between the rings, spirocycloalkyl groups are divided into monospirocycloalkyl groups, dispirocycloalkyl groups or polyspirocycloalkyl groups, and spirocycloalkyl groups include, but are not limited to:
[0056] [ka]
[0057] "Fused cycloalkyl group" refers to an all-carbon polycyclic group in which each ring in the system shares an adjacent pair of carbon atoms with another ring in the system, one or more of which may contain one or more (preferably one, two or three) double bonds, but no ring has a completely conjugated pi-electron system. Depending on the number of constituent rings, fused cycloalkyl groups can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl groups, including, but not limited to, the following:
[0058] [ka]
[0059] "Bridged cycloalkyl group" refers to an all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected, and these groups may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π-electron system. Depending on the number of constituent rings, bridged cycloalkyl groups can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl groups, including but not limited to the following:
[0060] [ka]
[0061] The cycloalkyl ring may be fused to an aryl, heteroaryl, or heterocycloalkyl ring, where the ring connected to the parent structure is a cycloalkyl group, including, but not limited to, indanyl, tetrahydronaphthyl, benzocycloheptyl, and the like.
[0062] A "cycloalkyl group" or a "carbocycle" may be optionally substituted or unsubstituted, but if substituted, the substituents are independently deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 It is preferable that the number of the groups is one or more (preferably 1, 2, 3 or 4) selected from the following:
[0063] "Heterocyclic group" or "heterocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent. The partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably one, two, or three) double bonds, but none of the rings has a completely conjugated pi-electron system. One or more (preferably one, two, three, or four) ring atoms of the heterocyclic group are N, O, N.O, or S(O). r (where r is an integer of 0, 1, or 2), but does not include a ring portion of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. Preferably, it is a heterocyclic group containing 3 to 12, 3 to 8, or 3 to 6 ring atoms. For example, a "3- to 6-membered heterocyclic group" refers to a heterocyclic group containing 3 to 6 ring atoms, a "3- to 8-membered heterocyclic group" refers to a heterocyclic group containing 3 to 8 ring atoms, a "4- to 8-membered heterocyclic group" refers to a heterocyclic group containing 4 to 8 ring atoms, a "4- to 10-membered heterocyclic group" refers to a heterocyclic group containing 4 to 10 ring atoms, a "5- to 8-membered heterocyclic group" refers to a heterocyclic group containing 5 to 8 ring atoms, and a "3- to 12-membered heterocyclic group" refers to a heterocyclic group containing 3 to 12 ring atoms.
[0064] Monocyclic heterocyclic groups include, but are not limited to, pyrrolidyl, piperidyl, piperazyl, morpholyl, thiomorpholyl, homopiperazyl, oxetane, tetrahydrofuran, and the like.
[0065] Polycyclic heterocycles include spiro, fused and bridged heterocyclic groups. A "spiro heterocyclic group" is a polycyclic heterocyclic group that shares an atom (called a spiro atom) between monocyclic rings, one or more (preferably 1, 2, 3 or 4) of which ring atoms are N, O, N.O or S(O). r (where r is an integer 0, 1, 2), with the remaining ring atoms being carbon. These groups may contain one or more double bonds (preferably 1, 2 or 3), but no ring has a completely conjugated pi-electron system. Depending on the number of spiro atoms shared between the rings, spiroheterocyclic groups are classified as monospiroheterocyclic groups, dispiroheterocyclic groups or polyspiroheterocyclic groups. Spiroheterocyclic groups include, but are not limited to:
[0066] [ka]
[0067] "Fused heterocyclic group" refers to a polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with another ring in the system, one or more (preferably 1, 2, 3 or 4) rings may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated pi-electron system and one or more (preferably 1, 2, 3 or 4) ring atoms are N, O, N.O or S(O). r (wherein r is an integer of 0, 1, or 2), and the remaining ring atoms are carbon. Depending on the number of constituent rings, the heterocyclic groups can be divided into bicyclic, tricyclic, tetracyclic, or polycyclic fused heterocyclic groups, and the fused heterocyclic groups include, but are not limited to, the following:
[0068] [ka]
[0069] The term "bridged heterocyclic group" refers to a polycyclic heterocyclic group in which any two rings share two atoms that are not directly linked, and these rings may contain one or more (preferably one, two or three) double bonds, but no ring has a completely conjugated pi-electron system, and one or more (preferably one, two, three or four) ring atoms are N, O, N.O or S(O). r (wherein r is an integer of 0, 1, or 2), and the remaining ring atoms are carbon. Depending on the number of constituent rings, the bridged heterocyclic group can be divided into bicyclic, tricyclic, tetracyclic, or polycyclic bridged heterocyclic groups, and bridged heterocyclic groups include, but are not limited to, the following:
[0070] [ka]
[0071] The ring of the heterocyclic group may be fused to a ring of an aryl group, a heteroaryl group, or a cycloalkyl group, where the ring connected to the parent structure is a heterocyclic group, including, but not limited to, the following:
[0072] [ka]
[0073] A "heterocyclic group" or "heterocycle" may be optionally substituted or unsubstituted, but if substituted, the substituents are independently deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 It is preferable that the number of the groups is one or more (preferably 1, 2, 3 or 4) selected from the following:
[0074] The term "aryl group" or "aromatic ring" refers to an all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group having a conjugated pi-electron system, preferably an all-carbon aryl group containing 6-10 or 6-8 carbons, e.g., "C 6-10 "Aryl group" refers to an all-carbon aryl group containing 6-10 carbons, including, but not limited to, phenyl and naphthyl groups. 6-8 "Aryl group" refers to an all-carbon aryl group containing 6-8 carbons, wherein the ring of the aryl group may be fused to a heteroaryl group, a heterocyclic group, or a cycloalkyl ring, where the ring connected to the parent structure is an aryl ring, including, but not limited to, the following:
[0075] [ka]
[0076] The "aryl group" or "aromatic ring" may be substituted or unsubstituted, but if substituted, the substituents are independently deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 It is preferable that the number of the groups is one or more (preferably 1, 2, 3 or 4) selected from the following:
[0077] A "heteroaryl group" or "heteroaromatic ring" refers to a heteroaromatic system containing one or more (preferably 1, 2, 3 or 4) heteroatoms, including N, O, N.O and S(O)r, where r is an integer 0, 1 or 2, and preferably 5-10, 5-8 or 5-6 ring atoms. For example, a "5-8 membered heteroaryl group" refers to a heteroaromatic system containing 5-8 ring atoms, and a "5-10 membered heteroaryl group" refers to a heteroaromatic system containing 5-10 ring atoms, including, but not limited to, furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, and the like. The ring of the heteroaryl group may be fused to an aryl group, a heterocyclic group, or a cycloalkyl ring, where the ring connected to the parent structure is a heteroaryl ring, including, but not limited to:
[0078] [ka]
[0079] A "heteroaryl group" or "heteroaromatic ring" may be optionally substituted or unsubstituted, and if substituted, the substituents are independently deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 It is preferable that the number of the groups is one or more (preferably 1, 2, 3 or 4) selected from the following:
[0080] The term "alkenyl group" refers to an alkyl group as defined above, consisting of at least two carbon atoms and at least one carbon-carbon double bond, and is preferably a straight or branched chain containing alkenyl group containing 2-10 or 2-4 carbons. For example, "C 2-10 "Alkenyl group" refers to a straight or branched chain alkenyl group containing 2-10 carbons. 2-4The term "alkenyl group" refers to straight or branched chain alkenyl groups containing 2-4 carbons, including, but not limited to, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, and 3-butenyl groups.
[0081] The "alkenyl group" may be substituted or unsubstituted, but if substituted, the substituents are independently deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 It is preferable that the number of the groups is one or more (preferably 1, 2, 3 or 4) selected from the following:
[0082] The term "alkynyl group" refers to an alkyl group as defined above that consists of at least two carbon atoms and at least one carbon-carbon triple bond, but is preferably a straight or branched chain alkynyl group containing 2-10 or 2-4 carbons. For example, "C 2-10 "Alkynyl group" refers to a straight or branched chain alkynyl group containing 2-10 carbons. 2-4 The term "alkynyl group" refers to straight or branched chain alkynyl groups containing 2-4 carbons, including, but not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, and 3-butynyl groups.
[0083] The "alkynyl group" may be substituted or unsubstituted, but if substituted, the substituents are independently deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 It is preferable that the number of the groups is one or more (preferably 1, 2, 3 or 4) selected from the following:
[0084] The term "alkoxy group" refers to an -O-alkyl group, the alkyl group being as defined above. For example, "C 1-10 An "alkoxy group" refers to an alkyloxy group containing 1-10 carbon atoms. 1-4"Alkoxy group" refers to an alkyloxy group containing 1-4 carbon atoms, and "C 1-2 "Alkoxy" refers to alkyloxy groups containing 1-2 carbons, including, but not limited to, methoxy, ethoxy, propoxy, butoxy, and the like.
[0085] The "alkoxy group" may be optionally substituted or unsubstituted, but if substituted, the substituents are independently deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 It is preferable that the number of the groups is one or more (preferably 1, 2, 3 or 4) selected from the following:
[0086] The term "cycloalkoxy group" or "cycloalkyloxy group" refers to an -O-cycloalkyl group, the cycloalkyl group being as defined above. For example, "C 3-12 "Cycloalkoxy group" refers to a cycloalkyloxy group containing 3-12 carbons. 3-6 "Cycloalkoxy" refers to a cycloalkyloxy group containing 3-6 carbons, including, but not limited to, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, and the like.
[0087] The "cycloalkoxy group" or "cycloalkyloxy group" may be optionally substituted or unsubstituted, but if substituted, the substituents are independently deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17, -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 It is preferable that the number of the groups is one or more (preferably 1, 2, 3 or 4) selected from the following:
[0088] The term "heterocyclooxy" or "heterocyclyloxy" refers to an -O-heterocycle, where heterocycle is as defined above, and includes, but is not limited to, azetidinyloxy, oxetanyloxy, azacyclopentaoxy, nitrogen, oxanyloxy, and the like.
[0089] The "heterocyclooxy group" or "heterocyclic oxy group" may be optionally substituted or unsubstituted, but if substituted, the substituents are independently deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 16 )R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-OS(O)2R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 )R 19 , -C 0-8 Alkyl-OR 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-SC(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-OC(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 )R 21 , -C0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 It is preferable that the number of the groups is one or more (preferably 1, 2, 3 or 4) selected from the following:
[0090] "C 1-10 "Alkanoyl group" means C 1-10 This refers to the monovalent atomic group remaining after removing the hydroxyl group from an alkyl acid. 0-9 For example, "C1 alkyl-C(O)-" refers to an acetyl group, "C2 alkyl-C(O)-" refers to a propionyl group, and "C3 alkyl-C(O)-" refers to a butyryl group or an isobutyryl group.
[0091] "-C 0-8 Alkyl-S(O)(=NR 16 )R 17 " is -S(O)(=NR 16 )R 17 The sulfur atom in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0092] "-C 0-8 Alkyl-N=S(O)R 17 R 18 " is -N=S(O)R 17 R 18 The nitrogen atom in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0093] "-C 0-8 Alkyl-N=SR 17 R 18 " is -N=SR 17 R 18The nitrogen atom in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0094] "-C 0-8 Alkyl-OS(O)2R 19 " -OS(O)2R 19 The oxygen atom in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0095] "-C 0-8 Alkyl-S(O) r R 19 " -S(O) r R 19 The sulfur atom in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0096] "-C 0-8 Alkyl-P(O)(OR 20 )R 19 " is -P(O)(OR 20 )R 19 The phosphorus atom in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0097] "-C 0-8 Alkyl-OR 20 " -OR 20 The oxygen atom in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0098] "-C 0-8 Alkyl-C(O)OR 20 "What is C(O)OR? 20 The carbonyl group in 0-8 It refers to a group linked to an alkyl group, 0-8The alkyl group is as defined above.
[0099] "-C 0-8 Alkyl-C(O)SR 20 "What is -C(O)SR 20 The carbonyl group in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0100] "-C 0-8 Alkyl-SC(O)R 21 "What is SC(O)R? 21 The sulfur atom in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0101] "-C 0-8 Alkyl-C(O)R 21 "What is -C(O)R 21 The carbonyl group in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0102] "-C 0-8 Alkyl-OC(O)R 21 "What is OC(O)R? 21 The oxygen atom in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0103] "-C 0-8 Alkyl-NR 22 R 22 " -NR 21 R 22 The nitrogen atom in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0104] "-C 0-8 Alkyl-C(=NR 22)R 21 " is -C(=NR 22 )R 21 The carbon atom in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0105] "-C 0-8 Alkyl-N(R 22 )-C(=NR 23 )R 21 " is -N(R 22 )-C(=NR 23 )R 21 The nitrogen atom in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0106] "-C 0-8 Alkyl-C(O)NR 22 R 23 " is -C(O)NR 22 R 23 The carbonyl group in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0107] "-C 0-8 Alkyl-N(R 22 )-C(O)R 21 " is -N(R 22 )-C(O)R 21 The nitrogen atom in 0-8 It refers to a group linked to an alkyl group, 0-8 The alkyl group is as defined above.
[0108] "Halo-substituted C 1-10 The term "alkyl group" refers to an alkyl group of 1 to 10 carbons in which a hydrogen atom in the alkyl group is optionally replaced by an atom of fluorine, chlorine, bromine, or iodine, including, but not limited to, difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, and the like.
[0109] "Halo-substituted C 1-10 The term "alkoxy group" refers to a 1-10 carbon alkoxy group in which the hydrogen in the alkyl group is optionally replaced by an atom of fluorine, chlorine, bromine, or iodine. Examples of the alkoxy group include, but are not limited to, difluoromethoxy, dichloromethoxy, dibromomethoxy, trifluoromethoxy, trichloromethoxy, and tribromomethoxy.
[0110] Deuterium substitution C 1-10 "Alkyl group" refers to a 1-10 carbon alkyl group in which a hydrogen in the alkyl group is optionally replaced by a deuterium atom, including, but not limited to, deuteromethyl, dideuteromethyl, trideuteromethyl, and the like.
[0111] "Halogen" refers to fluorine, chlorine, bromine, or iodine. "n-BuLi" refers to normal butyl lithium. "THF" refers to tetrahydrofuran. "m-CPBA" refers to metachloroperbenzoic acid. "CuCN" refers to cuprous cyanide. "DMF" refers to dimethylformamide. "K2CO3" refers to potassium carbonate. "dioxane" refers to dioxane. "NBS" refers to N-bromosuccinimide. "MeCN" refers to acetonitrile. "DMSO" refers to dimethylsulfoxide.
[0112] "Optional" or "optionally" means that the event or circumstance described below may, but does not necessarily, occur, and the description includes cases where the event or circumstance occurs or does not occur, i.e., substituted or unsubstituted. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may, but does not necessarily, be present, and the description includes cases where the heterocyclic group is substituted with an alkyl group and cases where the heterocyclic group is not substituted with an alkyl group.
[0113] "Substitution" refers to the substitution of one or more "hydrogen atoms" in a group with a corresponding number of substituents, independently of each other. Of course, the substituents are only those that are chemically possible, and conform to the theory of chemical valence bonds, so that a person skilled in the art can confirm (experimentally or theoretically) whether or not substitution is possible without any special effort. For example, an amino group or a hydroxy group having a free hydrogen may be unstable when bonded to a carbon atom having an unsaturated bond (e.g., an olefin).
[0114] "Stereoisomer" means an isomer that arises due to the difference in the spatial arrangement of atoms in a molecule. It can be divided into two types, cis-trans isomers and enantiomers, and can also be divided into two types, enantiomers and diastereoisomers. Stereoisomers that arise due to the rotation of a single bond are called conformational stereoisomers, also called rotamers. Stereoisomers that arise due to bond length, bond angle, double bonds in a molecule, the presence of rings, etc. are called configuration stereoisomers, and structural stereoisomers are divided into two types. Among them, isomers that arise due to the inability to freely rotate the double bonds or single bonds of ring carbon atoms are called geometric isomers, also called cis-trans isomers, and are divided into two structures, Z and E. For example, cis-2-butene and trans-2-butene are a pair of geometric isomers, and stereoisomers with different optical properties resulting from the lack of antiaxial symmetry in the molecule are called optical isomers, and are divided into structures R and S. In the present invention, the "stereoisomer" may be understood to include one or more of the enantiomers, structural stereoisomers, and conformational isomers, unless otherwise specified.
[0115] In the present invention, the term "pharmaceutical acceptable salt" refers to a pharmaceutical acceptable acid addition salt, including inorganic acid salts and organic acid salts, which can be prepared by methods known in the art.
[0116] A "pharmaceutical composition" refers to a mixture of one or more compounds described herein, or physiological / pharmaceutical salts or prodrugs thereof, and other chemical components, and other components, such as physiological / pharmaceutical carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism and to exert a biological activity by contributing to the absorption of the active ingredient.
[0117] The present invention will be described in more detail and comprehensively below with reference to examples. However, the present invention is not limited to the examples, and the present invention is not limited to the contents of the examples. The structures of the compounds of the present invention were confirmed by nuclear magnetic resonance (NMR) and / or liquid phase mass spectrometry (LC-MS). The chemical shifts (δ) of NMR are given in parts per million (ppm). NMR measurements were performed using a Bruker AVANCE-400 / 500 nuclear magnetic resonance instrument, with the solvents used being deuterated dimethylsulfoxide (DMSO-d6), deuterated methanol (CD3OD) and deuterated chloroform (CDCl3), and the internal standard was tetramethylsilane (TMS).
[0118] The liquid phase mass spectrometry (LC-MS) was performed using an Agilent 6120 mass spectrometer. The HPLC measurements were performed using an Agilent 1200DAD high pressure liquid phase chromatograph (Sunfire C18 150 × 4.6 mm chromatographic column) and a Waters 2695-2996 high pressure liquid phase chromatograph (Gimini C18 150 × 4.6 mm chromatographic column).
[0119] The silica gel plates used for thin layer chromatography were Yantai Yellow Sea HSGF254 or Qingdao GF254, with the specifications used for TLC being 0.15 mm~0.20 mm, and the specifications used for product separation and purification by thin layer chromatography were 0.4 mm~0.5 mm. For column chromatography, Yantai Yellow Sea silica gel with 200~300 mesh was usually used as the carrier.
[0120] The starting materials in the examples of the present invention are either known commercially or can be synthesized by methods known in the art. Unless otherwise stated, all reactions of the present invention are carried out under a dry nitrogen or argon atmosphere with continuous magnetic stirring, the solvents are dry solvents, and the reaction temperatures are in degrees Celsius (° C.).
[0121] 1. Manufacturing of intermediates Intermediate 1: Preparation of 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)-3-fluoro-1-naphthonitrile
[0122] [ka]
[0123] First step: Synthesis of 5-bromo-7-fluoro-9-methyl-1,4-dihydro-1,4-epiminonaphthalene
[0124] [ka]
[0125] 1,3-Dibromo-2-chloro-5-fluorobenzene (45.0 g, 156 mmol) and N-methyl-2-pyrrole (27.8 mL, 312 mmol) were dissolved in tetrahydrofuran (1000 mL), and n-butyllithium (65 mL, 162 mmol) was added dropwise at -30°C under nitrogen gas protection. After the addition was completed, the mixture was stirred at -30°C for 0.5 hours, and then at 25°C for 12 hours. The reaction solution was slowly poured into 1000 mL of water, extracted with ethyl acetate (1000 mL*3), washed with saturated aqueous sodium chloride solution (1000 mL), and the organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was separated using a high-speed silica gel column to obtain 5-bromo-7-fluoro-9-methyl-1,4-dihydro-1,4-epimino naphthalene (19.0 g, yield 48%). 1H NMR (400MHz, CDCl3) δ 7.16-6.62 (m, 4H), 4.85-4.44 (m, 2H), 2.32 (br s, 1H), 2.16 (br s, 1H), 2.06 (s, 1H), 1.81 (br s, 1H).
[0126] Second step: Synthesis of 1-bromo-3-fluoronaphthalene
[0127] [ka]
[0128] 5-Bromo-7-fluoro-9-methyl-1,4-dihydro-1,4-epiminonaphthalene (44.0 g, 173 mmol) was dissolved in chloroform (450 mL), m-CPBA (70.2 g, 85% purity, 346 mmol) was added slowly in several portions at 0°C, and the reaction solution was reacted at 25°C for 14 hours. The reaction solution was slowly poured into 500 mL of water, extracted with dichloromethane (500 mL*3), washed with saturated aqueous sodium sulfite solution (400 mL*2), washed with saturated saline (400 mL), the organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was separated using a high-speed silica gel column to obtain 1-bromo-3-fluoronaphthalene (34.0 g, yield 87%).
[0129] 1 H NMR (400MHz, CDCl3) δ 8.29-8.19 (m, 1H), 7.78 (br dd, J=2.9, 4.5 Hz, 1H), 7.67-7.52 (m, 3H), 7.50-7.41 (m, 1H).
[0130] Third step: Synthesis of 3-fluoro-1-naphthonitrile
[0131] [ka]
[0132] 1-Bromo-3-fluoronaphthalene (34.0 g, 151 mmol) was dissolved in DMF (450 mL), and copper(I) cyanide (23.2 mL, 755 mmol) was slowly added under nitrogen gas protection at 0° C. The mixture was reacted at 145° C. for 12 hours under nitrogen gas protection. The reaction solution was slowly poured into 250 mL of saturated saline, extracted with ethyl acetate, washed with saturated aqueous sodium chloride solution, and the organic phase was dried over anhydrous sodium sulfate, then concentrated under reduced pressure to remove the solvent, and the residue was separated using a high-speed silica gel column to obtain 3-fluoro-1-naphthonitrile (19.0 g, yield 66%).
[0133] 1 H NMR (400 MHz, CDCl3) δ 8.17 (m, 1H) 7.81 (m, 1H) 7.62 (m, 4H). Fourth step: Synthesis of 3-fluoro-2-iodo-1-naphthonitrile
[0134] [ka]
[0135] 3-Fluoro-1-naphthonitrile (1.89 g, 3.57 mmol) was dissolved in tetrahydrofuran (200 mL), and LDA (48.2 mL, 96.4 mmol) was slowly added dropwise under nitrogen gas protection. After the addition was completed, the reaction was carried out at -70°C for 30 minutes under nitrogen gas protection. Iodine (28.3 mL, 114 mmol) was dissolved in tetrahydrofuran (200 mL), and then added to the reaction solution at -70°C under nitrogen gas protection. The mixture was stirred at -70°C for 30 minutes, and then reacted at 25°C for 17 hours. After the reaction was completed, the mixture was diluted with water (300 mL), extracted with ethyl acetate (3 * 300 mL), washed with saturated aqueous sodium chloride solution (400 mL), and the organic phase was dried over anhydrous sodium sulfate, then concentrated under reduced pressure to remove the solvent. The residue was separated using a high-speed silica gel column to obtain 3-fluoro-2-iodo-1-naphthonitrile (16.0 g, yield 52%).
[0136] 1 H NMR (400MHz, CDCl3) δ 8.29-8.22 (m, 1H), 7.91-7.84 (m, 1H), 7.76-7.64 (m, 3H).
[0137] Fifth step: Synthesis of 3-fluoro-2-(1-methyl-1H-pyrazol-5-yl)-1-naphthonitrile
[0138] [ka]
[0139] 3-Fluoro-2-iodo-1-naphthonitrile (8.00 g, 26.9 mmol) was dissolved in 1,4-dioxane (80 mL) and water (16 mL), and the reaction solution was added with sodium bicarbonate (42.4 g, 505 mmol), potassium carbonate (608 mg, 4.40 mmol), 1-methyl-1H-pyrazole-5-boronic acid pinacol ester (14.0 g, 67.3 mmol) and Pd-118 (0.88 g, 1.34 mmol) under nitrogen gas protection. The reaction solution was reacted at 80° C. for 2 hours under nitrogen gas protection. The reaction mixture was extracted with ethyl acetate (80 mL*3), washed with saturated aqueous sodium chloride solution (200 mL), the organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was separated on a high-performance silica gel column to obtain 3-fluoro-2-(1-methyl-1H-pyrazol-5-yl)-1-naphthonitrile (6.0 g, yield 76%). MS m / z (ESI): 252 [M+H] + .
[0140] 1 H NMR (400MHz, CDCl3) δ 8.36-8.30 (m, 1H), 7.98-7.92 (m, 1H), 7.88 (d, J = 9.8 Hz, 1H), 7.77-7.73 (m, 2H), 7.69 (d, J = 2.0 Hz, 1H), 7.28 (s, 1H), 6.63 (d, J = 2.0 Hz, 1H), 3.86 (d, J = 1.5 Hz, 3H).
[0141] Sixth step: Synthesis of 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)-3-fluoro-1-naphthonitrile
[0142] [ka]
[0143] 3-Fluoro-2-(1-methyl-1H-pyrazol-5-yl)-1-naphthonitrile (6.00 g, 23.8 mmol) was dissolved in acetonitrile (500 mL), NBS (7.65 g, 42.9 mmol) was added, and the reaction solution was reacted at 25 ° C for 24 hours. After the reaction was completed, the reaction solution was extracted with water (100 mL) and ethyl acetate (100 mL * 3), washed with saturated sodium chloride aqueous solution (200 mL), the organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was separated with a high-speed silica gel column to obtain 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)-3-fluoro-1-naphthonitrile (8.00 g, yield 91%).
[0144] 1 H NMR (400MHz, DMSO-d6) δ 8.49 (d, J = 10.4 Hz, 1H), 8.27-8.19 (m, 2H), 7.93-7.85 (m, 3H), 3.81 (s, 3H).
[0145] Intermediate 2: Preparation of tert-butyl ((3-bromo-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-5-yl)methyl)carbamate
[0146] [ka]
[0147] First step: Synthesis of methyl 5-bromo-3-(bromomethyl)pyridine-2-carboxylate
[0148] [ka]
[0149] Methyl 5-bromo-3-methylpyridine-2-carboxylate (3.0g, 13.04mmol) and NBS (3.48g, 19.56mmol) were added to carbon tetrachloride (50mL), and the mixture was stirred under nitrogen gas protection at 80°C for 18 hours. The reaction solution was concentrated and then separated by column chromatography to obtain methyl 5-bromo-3-(bromomethyl)pyridine-2-carboxylate (4.0, yield 90%).
[0150] 1 H NMR (400MHz, DMSO-d6) δ 8.69 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 2.0 Hz, 1H), 4.89 (s, 2H), 4.02 (s, 3H).
[0151] Second step: Synthesis of 3-bromofuro[3,4-b]pyridin-7(5H)-one
[0152] [ka]
[0153] Methyl 5-bromo-3-(bromomethyl)pyridine-2-carboxylate (2000 mg, 6.47 mmol) and water (10 mL) were added to 1,4-dioxane (50 mL), and the mixture was stirred at 100° C. for 18 hours under nitrogen gas protection. The reaction solution was concentrated and then separated by column chromatography to give 3-bromofuro[3,4-b]pyridin-7(5H)-one (1.0 g, 61% yield). MS m / z (ESI): 213 / 215 [M+H] + .
[0154] Third step: Synthesis of (Z)-3-bromo-5-((dimethylamino)methylene)furo[3,4-b]pyridin-7(5H)-one
[0155] [ka]
[0156] 3-Bromofuro[3,4-b]pyridin-7(5H)-one (1.0 g, 4.67 mmol) and potassium tert-butoxide (52 mg, 0.47 mmol) were added to DMFDMA, and the mixture was stirred at 100° C. for 18 hours under nitrogen gas protection. The reaction solution was concentrated and then triturated with PE to give (Z)-3-bromo-5-((dimethylamino)methylene)furo[3,4-b]pyridin-7(5H)-one (1.0 g, 70% yield). MS m / z (ESI): 269 / 271 [M+H] + .
[0157] Fourth step: Synthesis of 3-bromo-5-((dimethylamino)methyl)pyrido[2,3-d]pyridazin-8(7H)-one
[0158] [ka]
[0159] (Z)-3-Bromo-5-((dimethylamino)methylene)furo[3,4-b]pyridin-7(5H)-one (7.0 g, 26.0 mmol) and hydrazine hydrate (7.44 mL, 130.1 mmol) were added to ethanol (50 mL), and the mixture was stirred at 80° C. for 18 hours under nitrogen gas protection. The reaction solution was concentrated and then separated by column chromatography to give 3-bromo-5-((dimethylamino)methyl)pyrido[2,3-d]pyridazin-8(7H)-one (3.0 g, 25% yield). MS m / z (ESI): 283 / 285 [M+H] + .
[0160] Fifth step: Synthesis of 3-bromo-5-(chloromethyl)pyrido[2,3-d]pyridazin-8(7H)-one
[0161] [ka]
[0162] 3-Bromo-5-((dimethylamino)methyl)pyrido[2,3-d]pyridazin-8(7H)-one (300 mg, 1.06 mmol) and chloromethanoic acid-2-methylpropyl ester (0.28 mL, 2.12 mmol) were added to THF (10 mL) and the mixture was stirred at room temperature for 4 hours under nitrogen gas protection. The reaction solution was concentrated and then triturated with PE to give 3-bromo-5-(chloromethyl)pyrido[2,3-d]pyridazin-8(7H)-one (250 mg, 38% yield). MS m / z (ESI): 275 / 277 [M+H] + .
[0163] Sixth step: Synthesis of 2-((3-bromo-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-5-yl)methyl)isoindoline-1,3-dione
[0164] [ka]
[0165] 3-Bromo-5-(chloromethyl)pyrido[2,3-d]pyridazin-8(7H)-one (1.5 g, 5.46 mmol) and phthalimide potassium salt (1.52 g, 8.20 mmol) were added to DMF (50 mL) and the mixture was stirred at 90° C. for 2 h under nitrogen gas protection. The reaction mixture was diluted with water, extracted with EtOAc, and the organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, concentrated, and then separated by column chromatography to give 2-((3-bromo-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-5-yl)methyl)isoindoline-1,3-dione (2.0 g, 95% yield). MS m / z (ESI): 385 / 387 [M+H] + .
[0166] Seventh step: Synthesis of 5-(aminomethyl)-3-bromopyrido[2,3-d]pyridazin-8(7H)-one
[0167] [ka]
[0168] 2-((3-bromo-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-5-yl)methyl)isoindoline-1,3-dione (1.0 g, 4.67 mmol) and hydrazine hydrate (498 mg, 15.58 mmol) were added to ethanol (200 mL), and the mixture was stirred at 70° C. for 18 hours under nitrogen gas protection. After concentrating the reaction solution, 5-(aminomethyl)-3-bromopyrido[2,3-d]pyridazin-8(7H)-one (900 mg, 67% yield) was obtained. MS m / z (ESI): 256 / 258 [M+H] + .
[0169] Eighth step: Synthesis of tert-butyl ((3-bromo-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-5-yl)methyl)carbamate
[0170] [ka]
[0171] 5-(aminomethyl)-3-bromopyrido[2,3-d]pyridazin-8(7H)-one (900 mg, 3.53 mmol), triethylamine (2.45 mL, 17.64 mmol) were placed in dichloromethane (100 mL), and di-tert-butyl dicarbonate (3.02 mL, 14.11 mmol) was added under nitrogen gas protection, and the mixture was stirred at room temperature for 18 hours. The reaction solution was diluted with water, extracted with EtOAc, and the organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, concentrated, and then separated by column chromatography to give tert-butyl ((3-bromo-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-5-yl)methyl)carbamate (300 mg, 23% yield). MS m / z (ESI): 355 / 357 [M+H] + .
[0172] Intermediate 3: Preparation of (4-((bis(tert-butoxycarbonyl)amino)methyl)-8-cyano-1-oxo-1,2-dihydrophthalazin-6-yl)boronic acid
[0173] [ka]
[0174] First step: Synthesis of 4-bromo-2-iodo-6-methylbenzoic acid A mixture of 4-bromo-2-methylbenzoic acid (100 g, 465.1 mmol), NIS (156.93 g, 697.5 mmol), and Pd(OAc)2 (10.44 g, 46.5 mmol) in DMF (600 mL) was degassed with nitrogen and then stirred at 100° C. for 3 h. The reaction mixture was extracted with ethyl acetate (1 L) and water (1 L), washed with saturated saline (1 L), and the organic phase was dried over anhydrous sodium sulfate and then concentrated under reduced pressure to remove the solvent. The residue was separated by column chromatography to give 4-bromo-2-iodo-6-methylbenzoic acid (120 g, 57% yield).
[0175] Second step: Synthesis of 5-bromo-7-iodo-1,3-dihydro-2-benzofuran-1-one
[0176] [ka]
[0177] 4-Bromo-2-iodo-6-methylbenzoic acid (60 g, 176.0 mmol), TBAB (109.2 mL, 352.0 mmol), and Na2O8S2 (99.5 mL, 1003.1 mmol) were added to a solution of CH3CN (600 mL), respectively. The mixture was stirred at 80 °C for 24 h. When the reaction was confirmed to be complete by TLC, the reaction solution was extracted with ethyl acetate (600 ml) and water (600 mL), washed with saturated brine (600 mL), and the organic phase was dried over anhydrous sodium sulfate and then concentrated under reduced pressure to remove the solvent. The residue was separated by column chromatography to obtain 5-bromo-7-iodo-1,3-dihydro-2-benzofuran-1-one (20 g, 33% yield).
[0178] 1 H NMR (400 MHz, DMSO-d6) δ 8.31 (d, J = 0.72 Hz, 1H), 8.04 (d, J = 1.07 Hz, 1H), 5.35 (s, 2H).
[0179] Third step: Synthesis of (3Z)-5-bromo-3-[(dimethylamino)methylethenyl]-7-iodo-1,3-dihydro-2-benzofuran-1-one
[0180] [ka]
[0181] Toluene (330 mL) was added to a flask containing 5-bromo-7-iodo-1,3-dihydro-2-benzofuran-1-one (33.5 g, 98.8 mmol), followed by [(tert-butoxy)(dimethylamino)methyl]dimethylamine (26.5 mL, 128.5 mmol). The mixture was stirred at 90° C. for 5 hours. When the reaction was complete by TLC, the mixture was filtered and the filter cake was dried to provide the compound (3Z)-5-bromo-3-[(dimethylamino)methylethenyl]-7-iodo-1,3-dihydro-2-benzofuran-1-one (20.1 g, 52% yield) as a yellow solid.
[0182] 1 H NMR (400 MHz, DMSO-d6) δ 7.96 (d, J = 1.19 Hz, 1H), 7.68 (d, J = 1.07 Hz, 1H), 7.07 (s, 1H), 3.12 (s, 6H).
[0183] Fourth step: Synthesis of 6-bromo-4-[(dimethylamino)methyl]-8-iodo-1,2-dihydrophthalazin-1-one
[0184] [ka]
[0185] A 500 mL flask was charged with a solution of (3Z)-5-bromo-3-[(dimethylamino)methylethenyl]-7-iodo-1,3-dihydro-2-benzofuran-1-one (18 g, 45.7 mmol) in ethanol (180 mL). o Hydrazine hydrate (5.2 mL, 105.1 mmol) was added at C, followed by stirring at 25° C. for 0.5 h and then at 50° C. for 18 h. The precipitate was directly filtered and dried under reduced pressure to give 6-bromo-4-[(dimethylamino)methyl]-8-iodo-1,2-dihydrophthalazin-1-one (11.73 g, 63% yield) as a white solid.
[0186] 1 H NMR (400 MHz, DMSO-d6) δ 8.53 (d, J = 1.67 Hz, 1H), 8.35 (d, J = 1.67 Hz, 1H), 3.56 (s, 2H), 2.18 (s, 6H).
[0187] Fifth step: Synthesis of 6-bromo-4-(chloromethyl)-8-iodo-1,2-dihydrophthalazin-1-one
[0188] [ka]
[0189] A mixture of 6-bromo-4-[(dimethylamino)methyl]-8-iodo-1,2-dihydrophthalazin-1-one (12 g, 29.48 mmol) in THF (140 mL) was degassed several times with N2 and cooled to 0°C, after which chloro(2-methylpropoxy)methane (13.8 mL, 106.1 mmol) was added dropwise and stirred at 25°C with nitrogen for 16 h. The reaction solution was extracted with ethyl acetate (100 mL) and water (100 mL), washed with saturated saline (100 ml), and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a white crude product. The crude product and MTBE (20 mL) were stirred at 25°C for 30 minutes. The mixture was filtered, and then the filter cake was dried to obtain the compound 6-bromo-4-(chloromethyl)-8-iodo-1,2-dihydrophthalazin-1-one (9.2 g, yield 78%) as a white solid.
[0190] 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.88 (s, 1H), 8.59 (d, J = 1.76 Hz, 1H), 8.27 (d, J = 1.76 Hz, 1H), 5.02 (s, 2H).
[0191] Sixth step: Synthesis of tert-butyl N-[(7-bromo-5-iodo-4-oxo-3,4-dihydrophthalazin-1-yl)methyl]-N-[(tert-butyl)carbonyl]carbamate
[0192] [ka]
[0193] Bis(tert-butoxycarbonyl)amine (5.16 g, 23.73 mmol) was added to THF (100 mL), and lithium bis(trimethylsilyl)amide (25.7 mL, 25.71 mmol) was added at 0°C under N2 atmosphere, and the mixture was stirred at -70°C for 1 h under N2 atmosphere. Then, a mixture of 6-bromo-4-(chloromethyl)-8-iodo-1,2-dihydrophthalazin-1-one (7.9 g, 19.80 mmol) in tetrahydrofuran (100 mL) was added to the mixture. The resulting mixture was stirred at -70°C for 2 h. The reaction mixture was quenched with saturated NH4Cl (100 ml), extracted with ethyl acetate (80 ml) and water (100 ml), washed with saturated brine (100 ml), and the organic phase was dried over anhydrous sodium sulfate and then concentrated under reduced pressure to remove the solvent. The residue was separated by column chromatography to obtain tert-butyl N-[(7-bromo-5-iodo-4-oxo-3,4-dihydrophthalazin-1-yl)methyl]-N-[(tert-butyl)carbonyl]carbamate (4.09 g, yield 33%).
[0194] 1 H NMR (400 MHz, DMSO-d6) δ ppm 12.69 (s, 1H), 8.60 (d, J = 1.76 Hz, 1H), 8.26 (d, J = 1.76 Hz, 1H), 4.98 (s, 2H), 1.39 (s, 18H). Seventh step: Synthesis of tert-butyl ((7-bromo-5-cyano-4-oxo-3,4-dihydrophthalazin-1-yl)methyl) (tert-butoxycarbonyl)carbamate
[0195] [ka]
[0196] In a 250 mL one-neck flask, tert-butyl N-[(7-bromo-5-iodo-4-oxo-3,4-dihydrophthalazin-1-yl)methyl]-N-[(tert-butyl)carbonyl]carbamate (1.4 g, 2.17 mmol), N,N-dimethylformamide (20 mL), and copper(I) cyanide (194 mg, 2.17 mmol) were added and stirred at 80° C. for 3 hours. The reaction solution was concentrated under reduced pressure, the residue was diluted with dichloromethane, washed with 5% aqueous ammonia and saturated saline, respectively, the organic phase was dried over anhydrous sodium sulfate, suction filtered, and the filtrate was concentrated under reduced pressure to obtain tert-butyl((7-bromo-5-cyano-4-oxo-3,4-dihydrophthalazin-1-yl)methyl)(tert-butoxycarbonyl)carbamate (1.1 g, purity 88%, yield 93%). MS m / z (ESI): 479 / 481 [M+H] + .
[0197] Eighth step: Synthesis of (4-((bis(tert-butoxycarbonyl)amino)methyl)-8-cyano-1-oxo-1,2-dihydrophthalazin-6-yl)boronic acid
[0198] [ka]
[0199] In a 100 mL one-neck flask, tert-butyl ((7-bromo-5-cyano-4-oxo-3,4-dihydrophthalazin-1-yl)methyl) (tert-butoxycarbonyl)carbamate (1.5 g, 93% purity, 2.91 mmol), 1,4-dioxane (20 mL), potassium acetate (857 mg, 8.73 mmol), 1,1-bis(diphenylphosphino)ferrocenedichloropalladium (213 mg, 0.29 mmol), and bis(pinacolato)diboron (2.22 g, 8.73 mmol) were added and reacted at 80° C. for 2 hours with stirring. The reaction mixture was concentrated under reduced pressure, and the residue was separated by reverse phase column chromatography to obtain (4-((bis(tert-butoxycarbonyl)amino)methyl)-8-cyano-1-oxo-1,2-dihydrophthalazin-6-yl)boronic acid (1090 mg, purity 65%, yield 55%). MS m / z (ESI): 445 [M+H] + .
[0200] Intermediates 4 to 7 can be produced by referring to all or part of the synthesis method of intermediate 1, intermediate 2 or intermediate 3 and selecting corresponding starting materials.
[0201] [Table 1] Intermediate 8 Preparation of 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)-4-chloro-6-(3,3-difluoroazetidin-1-yl)-3-fluorobenzonitrile
[0202] [ka] First step: Synthesis of 2-bromo-4-chloro-6-(3,3-difluoroazetidin-1-yl)-3-fluorobenzonitrile
[0203] [ka]
[0204] 2-Bromo-4-chloro-3,6-difluorobenzonitrile (100 mg, 0.40 mmol), potassium carbonate (219 mg, 1.58 mmol), and 3,3-difluoroazetidine hydrochloride (103 mg, 0.792 mmol) were dissolved in N-methylpyrrolidone (2 mL) and stirred at 75 ° C overnight. After the reaction was completed, the mixture was cooled to room temperature, water (20 mL) was added, and the reaction solution was extracted with ethyl acetate (30 mL * 3). The combined organic phase was washed with saturated saline, then dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the crude product was separated by column chromatography to obtain 2-bromo-4-chloro-6-(3,3-difluoroazetidin-1-yl)-3-fluorobenzonitrile (50 mg, yield 39%). 1 H NMR (400 MHz, CDCl3) δ 6.49 (d, J = 5.6 Hz, 1H), 4.53 (t, J = 11.7 Hz, 4H).
[0205] Second step: Synthesis of 4-chloro-6-(3,3-difluoroazetidin-1-yl)-3-fluoro-2-(1-methyl-1H-pyrazol-5-yl)benzonitrile
[0206] [ka]
[0207] 2-Bromo-4-chloro-6-(3,3-difluoroazetidin-1-yl)-3-fluorobenzonitrile (300 mg, 0.92 mmol), 1-methyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (249 mg, 1.20 mmol), and sodium bicarbonate (310 mg, 3.69 mmol) were dissolved in 1,4-dioxane (16 mL) and water (4 mL) and added with cataCXium A Pd G3 (67 mg, 0.09 mmol) under the protection of nitrogen gas. The reaction was stirred at 60°C for 40 hours under the protection of nitrogen gas. Saturated sodium bicarbonate solution (30 mL) was added to the reaction solution, followed by extraction with dichloromethane (30 mL*3). The combined organic phase was concentrated and the crude product was separated by column chromatography to give 4-chloro-6-(3,3-difluoroazetidin-1-yl)-3-fluoro-2-(1-methyl-1H-pyrazol-5-yl)benzonitrile (120 mg, 40% yield). MS m / z (ESI): 327 [M+H] + .
[0208] Third step: Synthesis of 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)-4-chloro-6-(3,3-difluoroazetidin-1-yl)-3-fluorobenzonitrile
[0209] [ka]
[0210] 4-Chloro-6-(3,3-difluoroazetidin-1-yl)-3-fluoro-2-(1-methyl-1H-pyrazol-5-yl)benzonitrile (120 mg, 0.37 mmol) was dissolved in anhydrous acetonitrile (5 mL) and NBS (98.0 mg, 0.55 mmol) was added. The reaction was stirred overnight at 50° C. After completion of the reaction, the reaction system was concentrated and the crude product was separated on a C18 reverse phase column to give 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)-4-chloro-6-(3,3-difluoroazetidin-1-yl)-3-fluorobenzonitrile (120 mg, 80.6% yield). MS m / z (ESI): 405 / 407 [M+1] + .
[0211] Intermediates 9 to 21 can be produced by referring to all or part of the synthesis method for intermediate 8 and selecting corresponding raw materials.
[0212] [Table 2] TIFF2024543188000060.tif232162TIFF2024543188000061.tif139162
[0213] Intermediate 24: Synthesis of 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)-6-cyclopropoxy-3-fluoro-4-(3-methoxypyrrolidin-1-yl)benzonitrile
[0214] [ka]
[0215] First step: Synthesis of 2-bromo-4-chloro-3,6-difluorobenzonitrile
[0216] [ka]
[0217] A mixture of 4-chloro-2,5-difluorobenzonitrile (25 g, 144.1 mmol), NBS (51.28 g, 288.1 mmol), palladium acetate (3.23 g, 14.4 mmol) and p-toluenesulfonic acid (11.59 mL, 72.0 mmol) in dichloroethane (250 mL) was degassed with nitrogen and then stirred at 75° C. for 12 hours. The reaction solution was extracted with dichloroethane (300 mL) and water (300 mL), washed with saturated saline (300 mL), and the organic phase was dried over anhydrous sodium sulfate, then concentrated under reduced pressure to remove the solvent. The residue was separated by column chromatography to obtain 2-bromo-4-chloro-3,6-difluorobenzonitrile (13.33 g, 38% yield).
[0218] Second step: Synthesis of 2-bromo-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
[0219] [ka]
[0220] A mixture of 2-bromo-4-chloro-3,6-difluorobenzonitrile (15 g, 59.4 mmol), cyclopropanol (5.18 g, 89.1 mmol), and potassium carbonate (20.53 g, 148.6 mmol) in DMF (200 mL) was degassed with nitrogen and then stirred at 75° C. for 2 hours. The reaction solution was extracted with ethyl acetate (200 mL) and water (200 mL), washed with saturated saline (200 ml), and the organic phase was dried over anhydrous sodium sulfate and then concentrated under reduced pressure to remove the solvent. The residue was separated by column chromatography to give 2-bromo-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile (8.1 g, 47% yield).
[0221] 1 H NMR (400 MHz, CDCl3) δ 7.28 (d, J = 5.63 Hz, 1H) 3.77 (dt, J = 8.63, 4.44 Hz, 1H) 0.83 (br d, J = 4.63 Hz, 4H). Third step: Synthesis of 4-chloro-6-cyclopropoxy-3-fluoro-2-(1-methyl-1H-pyrazol-5-yl)benzonitrile
[0222] [ka]
[0223] 2-Bromo-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile (5.0 g, 17.21 mmol), 1-methyl-5-tetramethyl-1,3,2-dioxaborolane-2-pyrazole, cesium carbonate (16.82 g, 51.63 mmol) were dissolved in water (20 mL) and dioxane (100 mL), degassed with nitrogen, Pd-118 (1.12 g, 1.72 mmol) was added, and the mixture was stirred at 80 ° C for 12 hours. The reaction solution was extracted with ethyl acetate (50 mL) and water (50 mL), washed with saturated saline (50 mL), and the organic phase was dried over anhydrous sodium sulfate, then concentrated under reduced pressure to remove the solvent, and the residue was separated by column chromatography to obtain 4-chloro-6-cyclopropoxy-3-fluoro-2-(1-methyl-1H-pyrazol-5-yl)benzonitrile (2.5 g, purity 80%, yield 50%).
[0224] 1 H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 2.01 Hz, 1H), 7.50 (d, J = 5.77 Hz, 1H), 6.52 (d, J = 1.76 Hz, 1H), 3.89 (dt, J = 8.91, 4.33 Hz, 1H), 3.83 (d, J = 1.00 Hz, 3H), 0.96 (m, 4H). Fourth step: Synthesis of 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
[0225] [ka]
[0226] 4-Chloro-6-cyclopropoxy-3-fluoro-2-(1-methyl-1H-pyrazol-5-yl)benzonitrile (4.8 g, 16.46 mmol) and NBS (5.86 g, 32.91 mmol) were dissolved in acetonitrile (50 mL) and stirred for 2 hours in a nitrogen atmosphere at 40 ° C. The reaction solution was extracted with ethyl acetate (50 mL) and water (50 mL), washed with saturated saline (50 mL), and the organic phase was dried over anhydrous sodium sulfate, then concentrated under reduced pressure to remove the solvent, and the residue was separated by column chromatography to obtain 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile (5 g, purity: 93%, yield 76%).
[0227] 1 H NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 7.48 (d, J = 5.88 Hz, 1H), 3.82 (m, 1H), 3.73 (s, 3H), 0.92-0.83 (m, 4H). Fifth step: Synthesis of 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)-6-cyclopropoxy-3-fluoro-4-(3-methoxypyrrolidin-1-yl)benzonitrile
[0228] [ka]
[0229] 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile (80 mg, 0.22 mmol) was dissolved in N-methylpyrrolidone (2 mL), 3-methoxypyrrolidine (59 mg, 0.43 mmol) and N,N-diisopropylethylamine (134 mg, 1.08 mmol) were added, and the reaction was stirred overnight at 130° C. in a sealed tube. After completion of the reaction, it was quenched by adding water, extracted with ethyl acetate, the organic phases were combined and then washed with water, the organic phase was dried, concentrated, and the crude product was separated by column chromatography to give 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)-6-cyclopropoxy-3-fluoro-4-(3-methoxypyrrolidin-1-yl)benzonitrile (85 mg, 79% yield). MS m / z (ESI): 435 / 437 [M+H] + .
[0230] Intermediates 25-34 can be produced by referring to all or part of the synthesis method of intermediate 24 and selecting corresponding raw materials.
[0231] [Table 3] TIFF2024543188000069.tif199161
[0232] II. Manufacturing of specific embodiments Example 1: Preparation of 1-(aminomethyl)-7-(5-(1-cyano-3-fluoronaphthalen-2-yl)-1-methyl-1H-pyrazol-4-yl)-4-oxo-3,4-dihydrophthalazine-5-carbonitrile
[0233] [ka]
[0234] First step: synthesis of tert-butyl (tert-butoxycarbonyl) ((5-cyano-7-(5-(1-cyano-3-fluoronaphthalen-2-yl)-1-methyl-1H-pyrazol-4-yl)-4-oxo-3,4-dihydrophthalazin-1-yl)methyl)carbamate
[0235] [ka]
[0236] In a 25 mL one-neck flask, (4-((bis(tert-butoxycarbonyl)amino)methyl)-8-cyano-1-oxo-1,2-dihydrophthalazin-6-yl)boronic acid (1.0 g, 70% purity, 1.58 mmol), 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)-3-fluoro-1-naphthonitrile (594 mg, 1.58 mmol), 1,4-dioxane (20 mL), water (5 mL), sodium carbonate (501 mg, 4.73 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (230 mg, 0.32 mmol) were added, and the reaction solution was stirred at 80°C for 3 hours. The reaction mixture was concentrated under reduced pressure, and the residue was separated by column chromatography to obtain tert-butyl (tert-butoxycarbonyl) ((5-cyano-7-(5-(1-cyano-3-fluoronaphthalen-2-yl)-1-methyl-1H-pyrazol-4-yl)-4-oxo-3,4-dihydrophthalazin-1-yl)methyl)carbamate (450 mg, 43% yield). MS m / z (ESI): 650 [M+H] + .
[0237] Second step: Synthesis of 1-(aminomethyl)-7-(5-(1-cyano-3-fluoronaphthalen-2-yl)-1-methyl-1H-pyrazol-4-yl)-4-oxo-3,4-dihydrophthalazine-5-carbonitrile
[0238] [ka]
[0239] tert-Butyl (tert-butoxycarbonyl) ((5-cyano-7-(5-(1-cyano-3-fluoronaphthalen-2-yl)-1-methyl-1H-pyrazol-4-yl)-4-oxo-3,4-dihydrophthalazin-1-yl)methyl)carbamate (135 mg, 0.015 mmol) was dissolved in dichloromethane (3.0 mL), trifluoroacetic acid (2.0 mL) was added, and the reaction solution was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, the residue was diluted with ethyl acetate, and the pH was adjusted to 9-10 with saturated sodium bicarbonate, separated, and the aqueous phase was extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was rotary evaporated under reduced pressure to give 1-(aminomethyl)-7-(5-(1-cyano-3-fluoronaphthalen-2-yl)-1-methyl-1H-pyrazol-4-yl)-4-oxo-3,4-dihydrophthalazine-5-carbonitrile (96 mg, 97% yield). MS m / z (ESI): 450 [M+H] + .
[0240] 1 H NMR (400 MHz, DMSO-d6) δ 12.75 (brs, 1H), 8.56 (d, J = 10.2 Hz, 1H), 8.48 (s, 1H), 8.30-8.24 (m, 2H), 8.20-8.12 (m, 1H), 7.91-7.85 (m, 3H), 3.83 (s, 3H), 3.46 (s, 2H). tert-Butyl (tert-butoxycarbonyl) ((5-cyano-7-(5-(1-cyano-3-fluoronaphthalen-2-yl)-1-methyl-1H-pyrazol-4-yl)-4-oxo-3,4-dihydrophthalazin-1-yl)methyl)carbamate (380 mg, 0.585 mmol) was separated on a chiral column to give tert-butyl (M)-(tert-butoxycarbonyl) ((5-cyano-7-(5-(1-cyano-3-fluoronaphthalen-2-yl)-1-methyl-1H-pyrazol-4-yl)-4-oxo-3,4-dihydrophthalazin-1-yl)methyl)carbamate (135 mg, yield: 35%), and tert-butyl (P)-(tert-butoxycarbonyl)((5-cyano-7-(5-(1-cyano-3-fluoronaphthalen-2-yl)-1-methyl-1H-pyrazol-4-yl)-4-oxo-3,4-dihydrophthalazin-1-yl)methyl)carbamate (182 mg, yield 46%) were obtained. The tert-butoxycarbonyl was then removed with trifluoroacetic acid to obtain the corresponding final products, Example 4 and Example 5, with specific data shown in the following table.
[0241] Examples 2 to 37 can be produced by referring to all or part of the synthesis method of Example 1 and selecting corresponding raw materials.
[0242] [Table 4] TIFF2024543188000074.tif238161TIFF2024543188000075.tif238162TIFF2024543188000076.tif240162TIFF2024543188000077.tif239162TIFF2024543188000078.tif240161TIFF2024543188000079.tif46161The nuclear magnetic data of the compounds prepared in the above examples are as follows.
[0243] [Table 5] TIFF2024543188000081.tif239161TIFF2024543188000082.tif239161TIFF2024543188000083.tif239161 TIFF2024543188000084.tif243161TIFF2024543188000085.tif239161TIFF2024543188000086.tif106161
[0244] [Biological measurements and evaluation] 1. Human colon cancer HCT116 cell proliferation inhibition test 1. HCT 116 MTAP knockout cells and MTAP wild-type cells were seeded into 96-well flat-bottom plates and cultured overnight in McCoy's 5A medium containing 10% fetal bovine serum + 1% penicillin-streptomycin at 37°C and 5% CO2.
[0245] 2. The next day, the compounds were dissolved in DMSO, and the compounds were diluted with DMSO and culture medium in sequence and transferred to the cell plate, with the final compound concentration of 10 μM, 4-fold dilution, 9 concentration gradients and DMSO control.
[0246] 3. The cells that were not treated with the compound were removed, and cell activity was detected using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). The operation was performed according to the kit's instruction manual, and then the cell plate was placed in an EnVision Multilabel Reader to detect the luminescent signal.
[0247] 4. At the same time, the cell plates treated with the compounds were continuously cultured at 37°C and 5% CO2 for 6 days. 5. Then, cell activity was detected using CellTiter-Glo in the same manner.
[0248] 6. Finally, the dose-response curve was drawn using the four-parameter dose-response curve module of GraphPad Prism v 9.2.0 software, and the proliferation inhibitory IC 50 (Unit: nM) was calculated.
[0249] [Table 6] From the biological activity data of the compounds in the specific examples, it can be seen that the series of compounds of the present invention have a strong inhibitory effect on the proliferation of human colon cancer HCT116 MTAP knockout cells at the cellular level, and have a weak inhibitory effect on MTAP wild-type HCT116 cells, and have higher selectivity than the positive compound MRTX-1979.
[0250] [Pharmacokinetics in mice] 1. Research Objective The purpose of this study is to study the pharmacokinetic behavior of some compounds of the present invention, each administered by single oral administration (PO) to ICR mice.
[0251] 2. Experimental Plan 2.1 Experimental drugs The compounds used in this study were derived from the compounds of the specific examples of the present invention.
[0252] 2.2 Experimental animals ICR mice, male, N=3. Source: Shanghai Xipur-Bikai Laboratory Animal Co., Ltd. 2.3 Drug preparation and administration Each compound was weighed and dissolved in a solvent of 20%PG + 10%Solutol HS15 + 70%pH3 citrate buffer, and then shaken and sonicated to obtain a colorless, transparent solution or suspension. After fasting overnight, nine mice were orally administered with a dose of 10 mg / kg.
[0253] 2.4 Sample Collection: Blood was collected from the submandibular vein at approximately 90 μL per time point, anticoagulated with sodium heparin, placed on ice, and centrifuged within 1 hour to separate plasma (centrifugation conditions: 8000 rpm, 6 min, 2-8°C). The collection times were 0, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours. Samples were stored in a refrigerator at -20°C.
[0254] 40 μL of plasma sample was added to 160 μL of ice-cold acetonitrile containing internal standard, vortexed for 3 minutes, and centrifuged at 11000 rpm for 5 minutes. 100 μL of the supernatant was placed in 100 μL of water, and 5 μL was injected into the LC / MS / MS for analysis (results are shown in the table below).
[0255] 2.5 Test results: PK results after a single oral administration (PO) of 10 mg / kg of compound to mice
[0256] [Table 7]
[0257] Experimental conclusion: In the mouse pharmacokinetic test, under oral administration conditions, the compounds of the examples of the present invention have the same C max and AUC were significantly increased, showing favorable pharmacokinetic properties and better prospects for development. [Liver microsome stability experiment] 1. Reagent manufacturing 1. Preparation of Buffer C: Buffer A: 1.0 L of 0.1 M potassium dihydrogen phosphate buffer (containing 1.0 mM EDTA).
[0258] Buffer B: 1.0 L of 0.1 M dipotassium hydrogen phosphate buffer (containing 1.0 mM EDTA). Buffer C: Add Buffer A to 700 mL Buffer B, stopping when the pH reaches 7.4.
[0259] 2. Preparation of 10 mM stock solution: Selected example compounds and control products were each dissolved in DMSO to give 10 mM stock solutions.
[0260] 500 μM solution: 10 μL of 10 mM stock solution was added to 190 μL ACN. · 1.5 μM dosing solution (dissolved in liver microsome solution, human liver microsomes purchased from Xenotech): 18.75 μL of 20 mg / mL liver microsomes were added to 479.75 μL buffer C, then 1.5 μL of the 500 μM solution was added and mixed evenly by shaking gently.
[0261] Preparation of 4.6 mM NADPH solution: NADPH was weighed out, and then an appropriate amount of buffer C was added to make a 6 mM NADPH solution.
[0262] II. Specific experimental plan 1. 30 μL of 1.5 μM dosing solution was added to wells set at different time points (0 min, 5 min, 15 min, 30 min, 45 min) on a 96-well plate with 2 replicates.
[0263] 2. Prepare 0 min samples: First, add 135 μL ACN (containing internal standard) to the 0 min wells, followed by 15 μL of 6 mM NADPH solution.
[0264] 3. Preheat the 96-well plate containing the 1.5 μM dosing solution and the NADPH solution in a 37°C water bath for 5 minutes.
[0265] 4. 15 μL of pre-warmed 6 mM NADPH solution was added to the wells at 5, 15, 30, and 45 minutes to start the reaction and begin timing.
[0266] 5. When the timer showed 5, 15, 30 and 45 minutes, the reaction was terminated by adding 135 μL ACN (containing internal standard). Vortex for 10 minutes and centrifuge the samples for 15 minutes at 5594×g in a centrifuge.
[0267] 6. 50 μL of the supernatant was taken from the centrifuged sample, transferred to a 96-well sample plate with 50 μL of water, mixed, and finally the sample was sent to LC-MS / MS for analysis, and the half-life was calculated from the test results. The experimental results are shown in the table below.
[0268] [Table 8]
[0269] Experimental conclusion: In the in vitro human liver microsome stability experiment, the compounds of the examples of the present invention have a half-life T 1 / 2 has been significantly improved, exhibiting better in vitro metabolic stability and better prospects for development.
[0270] All documents related to the present invention are incorporated herein by reference as if each document were individually incorporated by reference. After reading the above content of the present invention, it should be understood that those skilled in the art may make various changes and modifications to the present invention, and that equivalent forms thereof are within the scope of the claims of the present invention.
Claims
1. A compound of formula (I), a stereoisomer thereof or a pharma- ceutically acceptable salt thereof, 【Chemistry 1】 Here, L is a bond, O, S, C(O), C(O)O, C(O)NH, CH=CH, C≡C, S(O), S(O) 2 , N.R. 12 , S(O) 2 NH or CR 13 R 14 and X 1 , X 2 and X 3 are each independently N or CR 15 and R 1 is hydrogen, deuterium, hydroxyl group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 aryl and 5-10 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl group, C 3-12 Cycloalkoxy group, 3- to 12-membered heterocyclic group, 3- to 12-membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R 2 is hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl group, 5-10 membered heteroaryl group, -C 0-8 Alkyl-SF 5 , -C 0-8 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-O-S(O) 2 R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 ) R 19 , -C 0-8 Alkyl-O-R 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-S-C(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-O-C(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 ) R 21 , -C 0-8 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 Selected from R 3 , R 4 , R 5 , R 6 and R 7 are each independently hydrogen, deuterium, a halogen, a cyano group, a nitro group, an azide group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl group, 5-10 membered heteroaryl group, -C 0-8 Alkyl-SF 5 , -C 0-8 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-O-S(O) 2 R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 ) R 19 , -C 0-8 Alkyl-O-R 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-S-C(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-O-C(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 ) R 21 , -C 0-8 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 or R 3 , R 4 , R 5 , R 6 , R 7 two adjacent substituents form a 4-8 membered carbocyclic ring, a 4-8 membered heterocyclic ring, a 6-8 membered aromatic ring, or a 5-8 membered heteroaromatic ring with the moiety to which they are directly linked, said groups being independently selected from deuterium, halogen, a cyano group, a nitro group, an azide group, 1-10 Alkyl group, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, ═O, ═S, -C 0-8 Alkyl-SF 5 , -C 0-8 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-O-S(O) 2 R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 ) R 19 , -C 0-8 Alkyl-O-R 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-S-C(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-O-C(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 ) R 21 , -C 0-8 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R 8 is hydrogen, deuterium, hydroxyl group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 aryl and 5-10 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl group, C 3-12 Cycloalkoxy group, 3- to 12-membered heterocyclic group, 3- to 12-membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R 9 is hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl group, 5-10 membered heteroaryl group, -C 0-8 Alkyl-SF 5 , -C 0-8 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-O-S(O) 2 R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 ) R 19 , -C 0-8 Alkyl-O-R 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-S-C(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-O-C(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 ) R 21 , -C 0-8 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 Selected from R 10 and R 11 are each independently hydrogen, deuterium, a halogen, a cyano group, a nitro group, an azide group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl group, 5-10 membered heteroaryl group, -C 0-8 Alkyl-SF 5 , -C 0-8 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-O-S(O) 2 R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 ) R 19 , -C 0-8 Alkyl-O-R 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-S-C(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-O-C(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 ) R 21 , -C 0-8 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 or R 10 and R 11 is a carbon atom directly bonded to C(O), C 3-10 Cycloalkyl group, 3-10 membered heterocyclic group, C 6-10 aryl or 5-8 membered heteroaryl group, said groups being independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl group, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, ═O, ═S, -C 0-8 Alkyl-SF 5 , -C 0-8 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-O-S(O) 2 R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 ) R 19 , -C 0-8 Alkyl-O-R 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-S-C(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-O-C(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 ) R 21 , -C 0-8 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R 12 is hydrogen, deuterium, hydroxyl group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 aryl and 5-10 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl group, C 3-12 Cycloalkoxy group, 3- to 12-membered heterocyclic group, 3- to 12-membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R 13 and R 14 are each independently hydrogen, deuterium, a halogen, a cyano group, a nitro group, an azide group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl group, 5-10 membered heteroaryl group, -C 0-8 Alkyl-SF 5 , -C 0-8 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-O-S(O) 2 R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 ) R 19 , -C 0-8 Alkyl-O-R 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-S-C(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-O-C(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 ) R 21 , -C 0-8 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 or R 13 and R 14 is a carbon atom directly bonded to C(O), C 3-10 Cycloalkyl group, 3-10 membered heterocyclic group, C 6-10 aryl or 5-8 membered heteroaryl group, said groups being independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl group, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, ═O, ═S, -C 0-8 Alkyl-SF 5 , -C 0-8 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-O-S(O) 2 R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 ) R 19 , -C 0-8 Alkyl-O-R 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-S-C(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-O-C(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 ) R 21 , -C 0-8 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from Each R 15 are independently hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl group, 5-10 membered heteroaryl group, -C 0-8 Alkyl-SF 5 , -C 0-8 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-O-S(O) 2 R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 ) R 19 , -C 0-8 Alkyl-O-R 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-S-C(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-O-C(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 ) R 21 , -C 0-8 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 wherein the groups are independently selected from deuterium, halogen, cyano, nitro, azide, C 1-10 Alkyl group, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, ═O, ═S, -C 0-8 Alkyl-SF 5 , -C 0-8 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-O-S(O) 2 R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 ) R 19 , -C 0-8 Alkyl-O-R 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-S-C(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-O-C(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 ) R 21 , -C 0-8 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted with one or more substituents selected from 15 is hydrogen, then R 3 , R 4 , R 5 , R 6 and R 7 at least one of the following is a 3-8 membered nitrogen-containing heterocyclic group, said nitrogen atom being linked to a benzene ring: Each R 16 are independently hydrogen, deuterium, and C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-10 Cycloalkyl group, 3-10 membered heterocyclic group, C 6-10 Aryl group, 5-10 membered heteroaryl group, -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)R 21 Or -C 0-8 Alkyl-C(O)NR 22 R 23 The group is selected from deuterium, halogen, a cyano group, a nitro group, an azide group, C 1-10 Alkyl group, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, ═O, ═S, -C 0-8 Alkyl-SF 5 , -C 0-8 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-O-S(O) 2 R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 ) R 19 , -C 0-8 Alkyl-O-R 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-S-C(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-O-C(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 ) R 21 , -C 0-8 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from Each R 17 and R 18 are each independently hydrogen, deuterium, a hydroxyl group, or C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-10 Cycloalkyl group, 3-10 membered heterocyclic group, C 6-10 aryl group or a 5-10 membered heteroaryl group; or R 17 and R 18 forms a 3-10 membered heterocyclic group together with the sulfur atom to which it is directly linked, said group being selected from the group consisting of deuterium, halogen, cyano group, nitro group, azide group, C 1-10 Alkyl group, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5-10 membered heteroaryl groups, ═O, ═S, -C 0-8 Alkyl-SF 5 , -C 0-8 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-8 Alkyl-N=S(O)R 17 R 18 , -C 0-8 Alkyl-N=SR 17 R 18 , -C 0-8 Alkyl-O-S(O) 2 R 19 , -C 0-8 Alkyl-S(O) r R 19 , -C 0-8 Alkyl-P(O)(OR 20 ) R 19 , -C 0-8 Alkyl-O-R 20 , -C 0-8 Alkyl-C(O)OR 20 , -C 0-8 Alkyl-C(O)SR 20 , -C 0-8 Alkyl-S-C(O)R 21 , -C 0-8 Alkyl-C(O)R 21 , -C 0-8 Alkyl-O-C(O)R 21 , -C 0-8 Alkyl-NR 22 R 23 , -C 0-8 Alkyl-C(=NR 22 ) R 21 , -C 0-8 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-8 Alkyl-C(O)NR 22 R 23 and -C 0-8 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from Each R 19 are independently hydrogen, deuterium, a hydroxyl group, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl groups, 5- to 10-membered heteroaryl groups and -NR 22 R 23 wherein the groups are independently selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl group, C 3-12 Cycloalkoxy group, 3- to 12-membered heterocyclic group, 3- to 12-membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from Each R 20 are independently hydrogen, deuterium, and C 1-10 Alkyl group, C 2-10 Alkenyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 aryl and 5-10 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, cyano, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl group, C 3-12 Cycloalkoxy group, 3- to 12-membered heterocyclic group, 3- to 12-membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from Each R 21 are independently hydrogen, deuterium, a hydroxyl group, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl group, C 3-12 Cycloalkoxy group, 3- to 12-membered heterocyclic group, 3- to 12-membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22 R 23 wherein the groups are independently selected from deuterium, halogen, a hydroxy group, ═O, a cyano group, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl group, C 3-12 Cycloalkoxy group, 3- to 12-membered heterocyclic group, 3- to 12-membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from Each R 22 and R 23 are each independently hydrogen, deuterium, a hydroxyl group, or C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups, C 6-10 Aryl group, 5- to 10-membered heteroaryl group, sulfinyl group, sulfonyl group, methylsulfonyl group, isopropylsulfonyl group, cyclopropylsulfonyl group, p-toluenesulfonyl group, aminosulfonyl group, dimethylaminosulfonyl group, and C 1-10 alkanoyl groups, said groups being independently selected from deuterium, halogen, hydroxyl groups, =O, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl group, C 3-12 Cycloalkoxy group, 3- to 12-membered heterocyclic group, 3- to 12-membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group, amino group, C 1-10 Alkyl mono-substituted amino group, C 1-10 Alkyl bis-substituted amino group and C 1-10 alkanoyl groups, or R 22 and R 23 forms a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group together with the nitrogen atom to which it is directly bonded, and the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is preferably selected from the group consisting of deuterium, halogen, a hydroxyl group, ═O, C 1-10 Alkyl group, C 2-10 Alkenyl group, C 2-10 Alkynyl group, halo-substituted C 1-10 Alkyl group, deuterium-substituted C 1-10 Alkyl group, C 1-10 Alkoxy group, C 3-12 Cycloalkyl group, C 3-12 Cycloalkoxy group, 3- to 12-membered heterocyclic group, 3- to 12-membered heterocyclic oxy group, C 6-10 Aryl group, C 6-10 Aryloxy group, 5-10 membered heteroaryl group, 5-10 membered heteroaryloxy group, amino group, C 1-10 Alkyl monosubstituted amino group, C 1-10 Alkyl disubstituted amino groups and C 1-10 Optionally further substituted by one or more substituents selected from alkanoyl groups; The compound of formula (I), its stereoisomer or pharma- ceutically acceptable salt thereof, characterized in that each r is independently 0, 1 or 2.
2. L is a bond, O, S, C(O), S(O), S(O) 2 , N.R. 12 Or CR 13 R 14 and X 1 , X 2 and X 3 are each independently N or CR 15 and R 1 is hydrogen, deuterium, hydroxyl group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 aryl and 5-8 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl group, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R 2 is hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, -C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-O-S(O) 2 R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 ) R 19 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-S-C(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 ) R 21 , -C 0-4 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 Selected from R 3 , R 4 , R 5 , R 6 and R 7 are each independently hydrogen, deuterium, a halogen, a cyano group, a nitro group, an azide group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl group, 5-8 membered heteroaryl group, -C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-O-S(O) 2 R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 ) R 19 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-S-C(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 ) R 21 , -C 0-4 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 or R 3 , R 4 , R 5 , R 6 , R 7 two adjacent substituents form a 5-8 membered carbocyclic ring, a 5-8 membered heterocyclic ring, a 6 membered aromatic ring, or a 5-6 membered heteroaromatic ring with the moiety to which they are directly linked, said groups being independently selected from deuterium, halogen, a cyano group, a nitro group, an azide group, 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, —C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-O-S(O) 2 R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 ) R 19 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-S-C(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 ) R 21 , -C 0-4 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R 8 is hydrogen, deuterium, hydroxyl group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 aryl and 5-8 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl group, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R 9 is hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, -C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-O-S(O) 2 R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 ) R 19 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-S-C(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 ) R 21 , -C 0-4 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 Selected from R 10 and R 11 are each independently hydrogen, deuterium, a halogen, a cyano group, a nitro group, an azide group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, -C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-O-S(O) 2 R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 ) R 19 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-S-C(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 ) R 21 , -C 0-4 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 or R 10 and R 11 is a carbon atom directly bonded to C(O), C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 aryl or 5-6 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, cyano, nitro, azide, C 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, —C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-O-S(O) 2 R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 ) R 19 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-S-C(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 ) R 21 , -C 0-4 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R 12 is hydrogen, deuterium, hydroxyl group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 aryl and 5-8 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl group, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R 13 and R 14 are each independently hydrogen, deuterium, a halogen, a cyano group, a nitro group, an azide group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, -C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-O-S(O) 2 R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 ) R 19 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-S-C(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 ) R 21 , -C 0-4 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 or R 13 and R 14 is a carbon atom directly bonded to C(O), C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 aryl or 5-6 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, cyano, nitro, azide, C 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, —C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-O-S(O) 2 R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 ) R 19 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-S-C(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 ) R 21 , -C 0-4 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from Each R 15 are independently hydrogen, deuterium, halogen, cyano group, nitro group, azide group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, -C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-O-S(O) 2 R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 ) R 19 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-S-C(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 ) R 21 , -C 0-4 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 wherein the groups are independently selected from deuterium, halogen, cyano, nitro, azide, C 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, —C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-O-S(O) 2 R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 ) R 19 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-S-C(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 ) R 21 , -C 0-4 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted with one or more substituents selected from 15 is hydrogen, then R 3 , R 4 , R 5 , R 6 and R 7 at least one of the following is a 3-8 membered nitrogen-containing heterocyclic group, said nitrogen atom being linked to a benzene ring: Here, R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 and r are as defined in claim 1, 2. A compound of formula (I) according to claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof.
3. Each R 16 are independently hydrogen, deuterium, and C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, -S(O) r R 19 , -C(O)OR 20 , -C(O)R 21 or -C(O)NR 22 R 23 The group is selected from deuterium, halogen, a cyano group, a nitro group, an azide group, C 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, -SF 5 , -S(O)(=NR 16 ) R 17 , -N=S(O)R 17 R 18 , -N=SR 17 R 18 , -O-S(O) 2 R 19 , -S(O) r R 19 , -P(O)(OR 20 ) R 19 , -O-R 20 , -C(O)OR 20 , -C(O)SR 20 , -S-C(O)R 21 , -C(O)R 21 , —O—C(O)R 21 , -NR 22 R 23 , -C(=NR 22 ) R 21 , -N(R 22 ) -C(=NR 23 ) R 21 , -C(O)NR 22 R 23 and Il-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from Each R 17 and R 18 are each independently hydrogen, deuterium, a hydroxyl group, or C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 aryl or 5-8 membered heteroaryl group, or R 17 and R 18 forms a 4-6 membered heterocyclic group together with the sulfur atom to which it is directly linked, said group being selected from the group consisting of deuterium, halogen, cyano group, nitro group, azide group, C 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, -SF 5 , -S(O)(=NR 16 ) R 17 , -N=S(O)R 17 R 18 , -N=SR 17 R 18 , -O-S(O) 2 R 19 , -S(O) r R 19 , -P(O)(OR 20 ) R 19 , -O-R 20 , -C(O)OR 20 , -C(O)SR 20 , -S-C(O)R 21 , -C(O)R 21 , —O—C(O)R 21 , -NR 22 R 23 , -C(=NR 22 ) R 21 , -N(R 22 ) -C(=NR 23 ) R 21 , -C(O)NR 22 R 23 and -N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from Each R 19 are independently hydrogen, deuterium, a hydroxyl group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl groups, 5-8 membered heteroaryl groups and -NR 22 R 23 wherein the groups are independently selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl group, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from Each R 20 are independently hydrogen, deuterium, and C 1-4 Alkyl group, C 2-4 Alkenyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 aryl and 5-8 membered heteroaryl groups, said groups being independently selected from deuterium, halogen, hydroxyl, ═O, cyano, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl group, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from Each R 21 are independently hydrogen, deuterium, a hydroxyl group, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 wherein the groups are independently selected from deuterium, halogen, a hydroxy group, ═O, a cyano group, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl group, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from Each R 22 and R 23 are each independently hydrogen, deuterium, a hydroxyl group, or C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, sulfinyl group, sulfonyl group, methylsulfonyl group, isopropylsulfonyl group, cyclopropylsulfonyl group, p-toluenesulfonyl group, aminosulfonyl group, dimethylaminosulfonyl group and C 1-4 alkanoyl groups, said groups being independently selected from deuterium, halogen, hydroxyl groups, =O, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl group, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group, amino group, C 1-4 Alkyl-substituted amino group, C 1-4 Alkyl-disubstituted amino group and C 1-4 alkanoyl groups, or R 22 and R 23 forms a 4-6 membered heterocyclic group or a 5-6 membered heteroaryl group together with the nitrogen atom to which it is directly bonded, and the 4-6 membered heterocyclic group or the 5-6 membered heteroaryl group is not deuterium, halogen, a hydroxy group, ═O, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl group, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group, amino group, C 1-4 Alkyl-substituted amino group, C 1-4 Alkyl-disubstituted amino group and C 1-4 Optionally further substituted by one or more substituents selected from alkanoyl groups; Each r is independently 0, 1 or 2; 2. A compound of formula (I) according to claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof.
4. The compound of formula (I) has the structure of the compound of formula (II): 【Chemistry 2】 Here, X 1 is N or CH, X 2 is N or CR 15 and R 1 is hydrogen, deuterium, C 1-4 Alkyl group, C 3-6 cycloalkyl groups and 3-6 membered heterocyclic groups, said groups being independently selected from deuterium, halogen, hydroxyl groups, ═O, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 Cycloalkyl group, C 3-6 Cycloalkoxy group, 3-6 membered heterocyclic group, 3-6 membered heterocyclic oxy group, C 6-8 Aryl group, C 6-8 Aryloxy group, 5-8 membered heteroaryl group, 5-8 membered heteroaryloxy group and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R 3 , R 4 , R 5 , R 6 and R 7 are each independently hydrogen, deuterium, halogen, cyano group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl group, 5-8 membered heteroaryl group, -C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-O-S(O) 2 R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 ) R 19 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-S-C(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 ) R 21 , -C 0-4 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 or R 3 , R 4 , R 5 , R 6 , R 7 two adjacent substituents form a 5-8 membered carbocyclic ring, a 5-8 membered heterocyclic ring, a 6 membered aromatic ring, or a 5-6 membered heteroaromatic ring with the moiety to which they are directly linked, said groups being independently selected from deuterium, halogen, cyano, C 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, —C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-O-S(O) 2 R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 ) R 19 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-S-C(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 ) R 21 , -C 0-4 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R 10 and R 11 are each independently hydrogen, deuterium, halogen, cyano group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, -C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 or R 10 and R 11 is a carbon atom directly bonded to C(O), C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 aryl or 5-6 membered heteroaryl groups, which groups are independently selected from deuterium, halogen, cyano, C 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-6 membered heterocyclic group, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, —C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R 15 is hydrogen, deuterium, cyano group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl group, 5-8 membered heteroaryl group, -C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-S(O)(=N-R 16 ) R 17 , -C 0-4 Alkyl-N=S(O)R 17 R 18 , -C 0-4 Alkyl-N=SR 17 R 18 , -C 0-4 Alkyl-O-S(O) 2 R 19 , -C 0-4 Alkyl-S(O) r R 19 , -C 0-4 Alkyl-P(O)(OR 20 ) R 19 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)SR 20 , -C 0-4 Alkyl-S-C(O)R 21 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(=NR 22 ) R 21 , -C 0-4 Alkyl-N(R 22 ) -C(=NR 23 ) R 21 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 wherein the groups are independently selected from deuterium, halogen, cyano, C 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, —C 0-4 Alkyl-SF 5 , -C 0-4 Alkyl-O-R 20 , -C 0-4 Alkyl-C(O)OR 20 , -C 0-4 Alkyl-C(O)R 21 , -C 0-4 Alkyl-O-C(O)R 21 , -C 0-4 Alkyl-NR 22 R 23 , -C 0-4 Alkyl-C(O)NR 22 R 23 and -C 0-4 Alkyl-N(R 22 )-C(O)R 21 and optionally further substituted with one or more substituents selected from 15 is hydrogen, then R 3 , R 4 , R 5 , R 6 and R 7 at least one of the following is a 3-8 membered nitrogen-containing heterocyclic group, said nitrogen atom being linked to a benzene ring: Here, R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 and r are as defined in claim 1, 2. A compound of formula (I) according to claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof.
5. The compound of formula (I) has the structure of a compound of formula (III): 【Chemistry 3】 Here, ring A has the following structure: 【Chemistry 4】 or 【Chemistry 5】 and R 1 is selected from hydrogen, deuterium, a methyl group, an ethyl group, an isopropyl group, and a cyclopropyl group; Each R 3 and R 7 are each independently hydrogen, deuterium, fluorine, chlorine, a cyano group, C 1-4 Alkyl group, C 3-8 Cycloalkyl groups, 3- to 8-membered heterocyclic groups, hydroxy groups, methoxy groups, ethoxy groups, isopropoxy groups, C 3-8 selected from a cycloalkoxy group, a 3- to 8-membered heterocyclic oxy group, a methylthio group, an ethylthio group, a carboxyl group, a methoxycarbonyl group, an ethoxycarbonyl group, an isopropoxycarbonyl group, an acetyl group, an acetoxy group, an amino group, a dimethylamino group, an acetylamino group, and a carbamoyl group; R 15 is selected from a cyano group, an ethynyl group, a cyclopropyl group, or hydrogen; R 15 is selected from a cyano group, an ethynyl group, or a cyclopropyl group, and ring A is 【Chemistry 6】 If R 4 and R 6a are each independently a halogen, C 1-4 Alkoxy group, C 3-8 A cycloalkoxy group, a 3- to 8-membered heterocyclic group, or a 3- to 8-membered heterocyclic oxy group, 1-4 Alkoxy group, C 3-8 The cycloalkoxy group, the 3- to 8-membered heterocyclic group, and the 3- to 8-membered heterocyclic oxy group each independently represent a deuterium atom, a halogen atom, a cyano group, 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, -SF 5 , -O-R 20 , -C(O)OR 20 , -C(O)R 21 , —O—C(O)R 21 , -NR 22 R 23 , -C(O)NR 22 R 23 and -N(R 22 )-C(O)R 21 and optionally further substituted by one or more substituents selected from R 15 is selected from a cyano group, an ethynyl group, or a cyclopropyl group, and ring A is 【Chemistry 7】 If R 6b is hydrogen, deuterium, fluorine, chlorine, cyano group, C 1-4 Alkyl group, C 3-8 Cycloalkyl groups, 3- to 8-membered heterocyclic groups, hydroxy groups, methoxy groups, ethoxy groups, isopropoxy groups, C 3-8 selected from a cycloalkoxy group, a 3- to 8-membered heterocyclic oxy group, a carboxyl group, an amino group, and a dimethylamino group; R 15 is selected from hydrogen and ring A is 【Chemistry 8】 If R 4 and R 6a are each independently a halogen, C 1-4 Alkoxy group, C 3-8 A cycloalkoxy group, a 3- to 8-membered heterocyclic group, or a 3- to 8-membered heterocyclic oxy group, 1-4 Alkoxy group, C 3-8 The cycloalkoxy group, the 3- to 8-membered heterocyclic group, and the 3- to 8-membered heterocyclic oxy group each independently represent a deuterium atom, a halogen atom, a cyano group, 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, -SF 5 , -O-R 20 , -C(O)OR 20 , -C(O)R 21 , —O—C(O)R 21 , -NR 22 R 23 , -C(O)NR 22 R 23 and -N(R 22 )-C(O)R 21 and optionally further substituted with one or more substituents selected from 4 and R 6a At least one of the nitrogen atoms is a 3-8 membered nitrogen-containing heterocyclic group, the nitrogen atom of which is bonded to a benzene ring, and the 3-8 membered nitrogen-containing heterocyclic group is free of deuterium, halogen, cyano group, C 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, -SF 5 , -O-R 20 , -C(O)OR 20 , -C(O)R 21 , —O—C(O)R 21 , -NR 22 R 23 , -C(O)NR 22 R 23 and -N(R 22 )-C(O)R 21 provided that the compound is optionally further substituted with one or more substituents selected from Here, R 20 , R 21 , R 22 and R 23 is as defined in claim 1, 2. A compound of formula (I) according to claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof.
6. The compound of formula (I) has the structure of a compound of formula (IVa): 【Chemistry 9】 Here, R 15 is selected from a cyano group, an ethynyl group, or a cyclopropyl group; Ring A has the following structure: 【Chemistry 10】 or 【Chemistry 11】 and R 4 and R 6a are each independently a halogen, C 1-4 Alkoxy group, C 3-8 A cycloalkoxy group, a 3- to 8-membered heterocyclic group, or a 3- to 8-membered heterocyclic oxy group, 1-4 Alkoxy group, C 3-8 The cycloalkoxy group, the 3- to 8-membered heterocyclic group, and the 3- to 8-membered heterocyclic oxy group each independently represent a deuterium atom, a halogen atom, a cyano group, 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, -SF 5 , -O-R 20 and -NR 22 R 23 and optionally further substituted by one or more substituents selected from R 6b is hydrogen, deuterium, fluorine, chlorine, cyano group, C 1-4 Alkyl group, C 3-8 Cycloalkyl groups, 3- to 8-membered heterocyclic groups, hydroxy groups, methoxy groups, ethoxy groups, isopropoxy groups, C 3-8 selected from a cycloalkoxy group, a 3- to 8-membered heterocyclic oxy group, a carboxyl group, an amino group, and a dimethylamino group; Here, R 20 , R 22 and R 23 is as defined in claim 5, 6. A compound of formula (I) according to claim 5, its stereoisomer or a pharma- ceutically acceptable salt thereof.
7. R 4 and R 6a are each independently selected from fluorine, chlorine, a cyclopropoxy group, a cyclobutoxy group, and a 3- to 8-membered nitrogen-containing heterocyclic group, and the cyclopropoxy group, cyclobutoxy group, and the 3- to 8-membered nitrogen-containing heterocyclic group are each independently selected from deuterium, fluorine, chlorine, a cyano group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a trifluoromethyl group, a difluoromethyl group, a trideuteromethyl group, a diduteromethyl group, a vinyl group, an ethynyl group, a cyclopropyl group, a cyclobutyl group, an oxetanyl group, an azetidinyl group, a phenyl group, -SF 5 , ═O, hydroxy group, methoxy group, ethoxy group, n-propyloxy group, isopropyloxy group, amino group, mono C 1-4 Alkylamino group and diC 1-4 optionally further substituted by one or more substituents selected from alkylamino groups; R 6b is selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, hydroxy, methoxy, ethoxy, isopropoxy, cyclopropoxy, cyclobutoxy, carboxyl, amino and dimethylamino groups; 7. A compound of formula (I) according to claim 6, its stereoisomer or a pharma- ceutically acceptable salt thereof.
8. The compound of formula (I) has the structure of a compound of formula (IVb): 【Chemistry 12】 Here, R 4 and R 6a are each independently a halogen, C 1-4 Alkoxy group, C 3-8 A cycloalkoxy group, a 3- to 8-membered heterocyclic group, or a 3- to 8-membered heterocyclic oxy group, 1-4 Alkoxy group, C 3-8 The cycloalkoxy group, the 3- to 8-membered heterocyclic group, and the 3- to 8-membered heterocyclic oxy group each independently represent a deuterium atom, a halogen atom, a cyano group, 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, -SF 5 , -O-R 20 and -NR 22 R 23 and optionally further substituted with one or more substituents selected from 4 and R 6a at least one of the nitrogen atoms is a 3-8 membered nitrogen-containing heterocyclic group, the nitrogen atom being linked to a benzene ring, and the 3-8 membered nitrogen-containing heterocyclic groups each independently include deuterium, halogen, a cyano group, C 1-4 Alkyl group, halo-substituted C 1-4 Alkyl group, deuterium-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3-8 membered heterocyclic groups, C 6-8 Aryl group, 5-8 membered heteroaryl group, ═O, ═S, -SF 5 , -O-R 20 and -NR 22 R 23 provided that the compound is optionally further substituted with one or more substituents selected from Here, R 20 , R 22 and R 23 is as defined in claim 5, 6. A compound of formula (I) according to claim 5, its stereoisomer or a pharma- ceutically acceptable salt thereof.
9. R 4 and R 6a are each independently selected from fluorine, chlorine, a cyclopropoxy group, a cyclobutoxy group, and a 3- to 8-membered nitrogen-containing heterocyclic group, and the cyclopropoxy group, cyclobutoxy group, and the 3- to 8-membered nitrogen-containing heterocyclic group are each independently selected from deuterium, fluorine, chlorine, a cyano group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a trifluoromethyl group, a difluoromethyl group, a trideuteromethyl group, a diduteromethyl group, a vinyl group, an ethynyl group, a cyclopropyl group, a cyclobutyl group, an oxetanyl group, an azetidinyl group, a phenyl group, -SF 5 , ═O, hydroxy group, methoxy group, ethoxy group, n-propyloxy group, isopropyloxy group, amino group, mono C 1-4 Alkylamino group and diC 1-4 and optionally further substituted with one or more substituents selected from alkylamino groups, 4 and R 6a at least one of the nitrogen atoms is a 3-8 membered nitrogen-containing heterocyclic group, the nitrogen atom being linked to a benzene ring, and the 3-8 membered nitrogen-containing heterocyclic groups each independently represent deuterium, fluorine, chlorine, a cyano group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a trifluoromethyl group, a difluoromethyl group, a trideuteromethyl group, a diduteromethyl group, a vinyl group, an ethynyl group, a cyclopropyl group, a cyclobutyl group, an oxetanyl group, an azetidinyl group, a phenyl group, -SF 5 , ═O, hydroxy group, methoxy group, ethoxy group, n-propyloxy group, isopropyloxy group, amino group, mono C 1-4 Alkylamino group and diC 1-4 provided that it is optionally further substituted by one or more substituents selected from alkylamino groups, 9. A compound of formula (I) according to claim 8, its stereoisomer or a pharma- ceutically acceptable salt thereof.
10. The 3-8 membered nitrogen-containing heterocyclic group is selected from the following structures: A compound of formula (I) according to claim 9, its stereoisomer or a pharma- ceutically acceptable salt thereof: 【Chemistry 13】
11. 11. A compound of formula (I) according to any one of claims 1 to 10, a stereoisomer thereof or a pharma- ceutically acceptable salt thereof, characterized in that it is selected from the following compounds: 【Chemistry 14】 【change】 【change】
12. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 11, its stereoisomer or a pharma- ceutically acceptable salt thereof and a medicament carrier.
13. Use of the compound of formula (I) according to any one of claims 1 to 11, its stereoisomer or its pharma- ceutically acceptable salt in the manufacture of a medicament for treating MATP-associated cancer or tumor.
14. The tumor or cancer may be endometrial adenocarcinoma, granulosaccinomas, testicular Sertoli cell tumors, germ cell tumors, malignant teratomas, squamous cell carcinomas, carcinoma in situ, adenocarcinomas, fibrosarcomas, melanomas, clear cell carcinomas, squamous cell carcinomas, botryoid sarcomas, fallopian tube carcinomas, adenocarcinomas, nephroblastomas, lymphomas, leukemias, bladder cancers, squamous cell carcinomas, transitional cell carcinomas, adenocarcinomas, prostate cancers, seminoma, teratomas, fetal carcinomas, teratomas, choriocarcinomas, sarcomas, interstitial cell carcinomas, fibromas, fibroadenomas, adenomatous tumors, lipomas, liver cancers, cholangiocarcinomas, hepatoblastomas , angiosarcoma, hepatocellular adenoma, hemangioma, gallbladder cancer, ampullary carcinoma, bile duct carcinoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, birthmark, dysplastic nevi, lipoma, hemangioma, acute and chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndromes, Hodgkin's disease, non-Hodgkin's lymphoma, osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, multiple myeloma, malignant macrocytoma Cyst chordoma, osteochondroma, benign chondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, giant cell tumor, angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma, myxoma, rhabdomyocele, fibroma, lipoma and teratoma, bronchopulmonary carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma, squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma, gastric cancer, lymphoma, leiomyosarcoma, ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, viperoma, adenocarcinoma, The tumor is selected from lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma, colon adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma, cranioma, hemangioma, granuloma, xanthomas, osteitis deformans, meningioma, meningeal sarcoma, gliomatosis, astrocytoma, medulloblastoma, glioma, ependymoma, germ cell tumor, glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumor, spinal neurofibroma, meningioma, glioma and sarcoma, 14. The application according to claim 13.
15. The cancer or tumor is selected from breast cancer, pancreatic cancer, skin cancer, bladder cancer, liver cancer, and head and neck cancer.
14. The application according to claim 13.
16. A compound of formula (I) according to any one of claims 1 to 11, a stereoisomer thereof or a pharma- ceutically acceptable salt thereof for use as a PRMT5 inhibitor.
Citation Information
Patent Citations
MTA-cooperative PRMT5 inhibitors
WO2021050915A1
MTA-cooperative PRMT5 inhibitors
WO2022192745A1
